РАСПАДАЮЩИЕСЯ ПЕРОРАЛЬНЫЕ ПЛЕНКИ

Изобретение относится к области медицины и химико-фармацевтической промышленности, в частности к водорастворимой пленке, распадающейся в ротовой полости, для доставки активного агента. Распадающаяся пленка включает, по крайней мере, один водорастворимый полимер и активный агент. В настоящем изобретении предлагаются также способы получения распадающейся пероральной пленки и применение распадающейся пленки для введения эффективной дозы активного агента в ротовую полость для абсорбции через слизистую оболочку ротовой полости. В некоторых вариантах распадающаяся пленка содержит по крайней мере один водорастворимый полимер и активный никотин. 2 н. и 5 з.п. ф-лы, 2 ил., 6 табл.

КОНЬЮГАТЫ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ НИКОТИНОВОЙ ЗАВИСИМОСТИ

Изобретение относится к конъюгатам, в частности представлен никотиновый гаптен-носитель формулы (III):W представляет собой -О- и находится в положении 5 пиридинового кольца; -(спейсер)- представляет собой С-Салкиленовую группу, С-Сциклоалкиленовую группу или С-Салкиленовую группу, прерванную 1-4 атомами кислорода и возможно прерванную группой -N(H)C(O)-; X* представляет собой -NH- или -S-; m означает 1; n означает целое число от 1 до 1000; и Y представляет собой возможно модифицированный белок-носитель, выбранный из бактериальных анатоксинов, иммуногенных веществ, вирусов, вирусоподобных частиц, белковых комплексов, белков, полипептидов, липосом и иммуностимулирующих комплексов, которые могут быть использованы для приготовления вакцин для лечения и/или предупреждения никотиновой зависимости. 2 н. и 6 з.п. ф-лы, 23 ил.,7 табл., 22 пр.

ВСПЕНЕННАЯ ПАСТИЛКА, СОДЕРЖАЩАЯ ПРИВИТОЙ СОПОЛИМЕР ПОЛИВИНИЛОВОГО СПИРТА И ПОЛИЭТИЛЕНГЛИКОЛЯ

Заявленное изобретение относится к химико-фармацевтической и косметической промышленности и касается пластинчатой формы доставки, растворяющейся или распадающейся в водной среде, для высвобождения, по меньшей мере, одного лекарственного или косметического действующего вещества в отверстие или полость в теле, включающей полимерную матрицу в виде затвердевшей пены с пространствами или полостями, а также, по меньшей мере, одно лекарственное или косметическое действующее вещество, отличающейся тем, что полимером матрицы является привитой сополимер поливинилового спирта и полиэтиленгликоля, состоящий на 75% из поливинилового спирта и на 25% из полиэтиленгликоля. Также описаны способы изготовления таких лекарственных форм. 3 н. и 3 з.п. ф-лы, 1 табл.

ГЕЛЬ И КРИСТАЛЛИЧЕСКИЙ ПОРОШОК

Изобретение относится к гелю и кристаллическому порошку, которые используют для получения раствора, используемого в устройстве обеспечения аэрозоля. Гель содержит воду в количестве от 1 до 20 мас.% по отношению к массе геля, никотин и водорастворимую кислоту, при этом молярное соотношение кислоты к никотину составляет от 3:1 до 1:3. Кроме того, предлагается кристаллический порошок, содержащий воду в количестве менее 15 мас.% по отношению к массе кристаллического порошка, никотин, водорастворимую кислоту, одно или несколько вкусоароматических веществ и инкапсулирующий материал. Изобретение позволяет получить гель, который легко растворяется без нагревания, позволяет избежать потери летучего никотина и/или вкусоароматического вещества в электронных сигаретах, а также который легко можно дегидрировать с получением кристаллического порошка для получения способной образовывать аэрозоль жидкости в электронных сигаретах. 8 н. и 27 з.п. ф-лы, 2 пр., 1 ил.

СПОСОБ И УСТРОЙСТВО ДЛЯ ИСПАРЕНИЯ И ИНГАЛЯЦИИ ВЫДЕЛЕННЫХ ВЕЩЕСТВ

Изобретение относится к медицинской технике. Описан элемент дозирования, содержащий рамку с отверстием и воздухопроницаемую пластину внутри отверстия. Пластина имеет отношение площади поверхности к массе по меньшей мере 1000 м/г и/или отношение площади поверхности к объему по меньшей мере 500 м/мл. 24 з.п. ф-лы, 15 ил.

ЧРЕСКОЖНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА НА ОСНОВЕ НИКОТИНА, ДОПОЛНИТЕЛЬНО СОДЕРЖАЩАЯ МОНОТЕРПЕНКЕТОНЫ

Изобретение относится к области создания лекарственных средств. Предложена чрескожная терапевтическая система, состоящая из подложки, по меньшей мере, одного содержащего никотин слой или участка, способного обладать способностью приклеиваться при надавливании, а также удаляемого защитного слоя, содержащая, по меньшей мере, одно эфирное масло, извлеченное из одной из разновидностей мяты, либо, по меньшей мере, один монотерпенкетон, содержащийся в таких эфирных маслах. Предложен также способ маскировки неприятного запаха чрескожной терапевтической системы, вызванного содержащимся в ней никотином. Предложенная система является наиболее нейтральной и приятной в использовании по сравнению с известными техническими решениями. 2 с. и 7 з.п.ф-лы, 1 табл., 1 ил.

КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ БОЛЕЗНИ ГЛАЗ, СВЯЗАННОЙ С НУКЛЕИНОВЫМИ КИСЛОТАМИ

Группа изобретений относится к области медицины, а именно к офтальмологии, и предназначена для лечения синдрома сухости глаз. Композиция для лечения синдрома сухости глаз, связанного с нуклеиновыми кислотами, который развивается в результате выработки/образования нуклеиновых кислот вместе с образованием глазных мукоидных пленок и/или биопленок, содержит дезоксирибонуклеазу I (ДНКазу I) и офтальмологическое вспомогательное вещество, и не содержит антибиотик. Композицию наносят на поверхность глаза для удаления нуклеиновой кислоты с поверхности глаза. Также обеспечивается способ лечения указанного синдрома сухости глаз, предусматривающий введение указанной композиции в глаз в эффективном количестве. Использование группы изобретений позволяет повысить эффективность лечения синдрома сухости глаз, связанного с нуклеиновыми кислотами, который развивается в результате выработки/образования нуклеиновых кислот вместе с образованием глазных мукоидных пленок и/или биопленок. 2 н. и 11 з.п. ф-лы, 16 ...

ИНГАЛЯТОР С ЗАВИХРЯЮЩЕЙ КОНЦЕВОЙ ВСТАВКОЙ

Группа изобретений относится к изделию в виде ингалятора. Изделие (100) содержит корпус (110), проходящий по продольной оси от конца мундштука до дальнего конца (114), полость (116) для капсулы, образованную внутри корпуса (110), воздушный канал (111) мундштука, проходящий от полости (116) для капсулы до конца (112) мундштука, и пробку (120), вставленную в дальний конец (114) и проходящую в полость (116) для капсулы. Пробка (120) проходит от дальней торцевой поверхности (124) пробки до внутреннего конца (122) пробки и содержит воздушный канал (113), проходящий от дальней торцевой поверхности (124) пробки до внутреннего конца (122) пробки. Воздушный канал (113) не является параллельным продольной оси и выполнен с возможностью стимулирования структуры завихряющегося потока воздуха в полости (116) для капсулы. Обеспечивается доставка частиц никотина в легкие при скоростях вдыхания или скоростях потока воздуха, которые находятся в пределах скоростей вдыхания или потока воздуха в обычном режиме ...

ДОЗОВЫЙ КАРТРИДЖ ДЛЯ ИНГАЛЯТОРА

Изобретение относится к медицинской технике. Описано устройство формирования, управления и/или введения измеренных доз веществ с целью применения в испаренном виде. В некоторых вариантах осуществления описаны дозовые картриджи, содержащие, по меньшей мере, одно вещество растительного происхождения, которые имеют нагревательный элемент, встроенный в картридж в непосредственном контакте с веществом растительного происхождения. В некоторых вариантах осуществления дозы, содержащиеся в картриджах, до использования хранятся в накопителе, необязательно в форме карусели. Транспортировка картриджа из накопителя в испаряющую камеру с электроприводом, которую приводит в действие нагревательный элемент, обеспечивается механическими средствами захвата. 26 з.п. ф-лы, 13 ил.

ТВЕРДЫЙ ПЕРОРАЛЬНЫЙ НИКОТИНОВЫЙ СОСТАВ

Группа изобретений относится к фармацевтической промышленности, а именно с составу для быстрого наступления ослабления тяги к никотину. Прессованная распадающаяся во рту никотиновая таблетка для быстрого наступления ослабления тяги к никотину, содержащая никотин и регулирующий рН агент, где таблетка предназначена для высвобождения содержания никотина в течение периода 90 секунд при взаимодействии со слюной ротовой полости и таблетка предназначена для высвобождения содержания регулирующего рН агента в течение периода 60 секунд при взаимодействии со слюной ротовой полости, где таблетка содержит по меньшей мере один полиол, при этом полиол составляет более 40 масс.% от массы таблетки, где по меньшей мере один полиол выбран из сорбита, эритрита, ксилита, мальтита, лактита, изомальта и их смесей, при этом таблетка содержит никотин в количестве от 0,5 мг до 10,0 мг, и при этом регулирующий рН агент представляет собой щелочной буферный агент. Прессованная распадающаяся во рту никотиновая таблетка ...

ТРАНСМУКОЗНАЯ СИСТЕМА ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Описываются способы получения и фармацевтические композиции липофильной ассоциации (LA) ионизирующегося фармацевтического средства и одного или нескольких липофильных веществ. LA находится в жидком состоянии при комнатной температуре или солюбилизирована в растворителе с меньшей, чем у воды, диэлектрической проницаемостью, в виде раствора LA при комнатной температуре. Растворителем предпочтительно является этанол, изопропиловый спирт, изопропилмиристат, изопропилпальмитат или глицерид. LA может быть адсорбирована или абсорбирована на носитель. Носителем предпочтительно является диоксид кремния и/или силикатированная микрокристаллическая целлюлоза. Фармацевтическое средство предпочтительно представляет собой никотин. Композиция по изобретению обеспечивает быстрое высвобождение фармацевтического средства при контакте с водой при рН, близком к физиологическому, и последующую его доставку в большой круг кровообращения. 4 н. и 27 з.п. ф-лы, 6 ил., 5 табл.

СИСТЕМА ТРАНСДЕРМАЛЬНОЙ ДОСТАВКИ НИКОТИНА

Настоящее изобретение относится к медицине. Описана система трансдермальной доставки никотина, содержащая адгезивный слой, содержащий никотин в форме свободного основания и жидкий ингредиент, совместимый с этим адгезивом, в которой адгезивный слой является сшитым, а жидкий ингредиент содержится в пропорции 20-75 вес. частей на 100 вес. частей адгезивного слоя в целом. Система трансдермальной доставки никотина обладает хорошей адгезивностью и когезией и одновременно обеспечивает низкую степень раздражения кожи во время снятия и приятное ощущение во время приклеивания. 6 з.п. ф-лы, 2 табл., 11 ил.

ПЛЕНКИ, РАСТВОРЯЮЩИЕСЯ В ПОЛОСТИ РТА

Изобретение относится к лекарственным средствам и касается композиции растворяющейся в полости рта пленки, обеспечивающей облегчение тяги к никотину, содержащей: а) энтеросолюбильный полимер; b) по меньшей мере, один щелочной буферный агент и с) никотиновый активный агент. Также раскрыты многокомпонентная растворяющаяся в полости рта пленка, обеспечивающая облегчение тяги к никотину, и способ получения растворяющейся в полости рта композиции пленки. Композиции по изобретению обеспечивают хорошую трансбуккальную абсорбцию и дают облегчение тяги к никотину у человека. 4 н. и 17 з.п. ф-лы.

ВДЫХАЕМЫЕ СОСТАВЫ НА ОСНОВЕ НИКОТИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Группа изобретений относится к сухому порошкообразному составу для вдыхания для имитирования эффектов курения. Сухой порошкообразный состав на основе никотина, содержащий частицы, где частицы содержат: соль никотина, по меньшей мере один сахар, и по меньшей мере одну аминокислоту, выбранную из группы, состоящей из глицина, лизина, лейцина и их комбинации, где частицы имеют размер от 1 до 7 микрон, где концентрация никотина составляет от 0,5% до 10% по весу, и концентрация по меньшей мере одного сахара составляет от 50% до 99% по весу, и где состав является подходящим для вдыхания для имитирования эффектов курения. Сухой порошкообразный состав на основе никотина, состоящий из частиц, содержащих никотин, по меньшей мере один сахар, ментол и по меньшей мере одну аминокислоту, выбранную из группы, состоящей из глицина, лизина и лейцина, где частицы имеют размер от 1 до 7 микрон, где концентрация никотина составляет от 0,5% до 10% по весу, и концентрация по меньшей мере одного сахара составляет ...

ВДЫХАЕМЫЕ НИКОТИНОВЫЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Изобретение относится к сухой порошковой никотиновой композиции, пригодной для ингаляции, причем композиция включает от 0,7 до 5% никотина, содержащего соль никотина, полученную из молочной кислоты, от 50 до 99% по меньшей мере одного сахара, содержащего трегалозу, и от 0,5 до 10% по меньшей мере одной аминокислоты. Технический результат заключается в обеспечении никотиносодержащей композиции для ингаляции. 3 н. и 20 з.п. ф-лы, 6 ил.

СОСТАВ, СОДЕРЖАЩИЙ НИКОТИН, С ПОКРЫТИЕМ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С БУФЕРНЫМИ СВОЙСТВАМИ, ПРИДАННЫМИ АМИНОКИСЛОТОЙ

Покрытый фармацевтический продукт для доставки субъекту никотина в любой форме содержит, по меньшей мере, одну сердцевину, никотин в любой форме и/или агент, имитирующий никотин, по меньшей мере, один слой покрытия и, необязательно, по меньшей мере, одну или несколько других добавок, где указанный, по меньшей мере, один слой покрытия содержит буферный агент, включающий, по меньшей мере, одну аминокислоту. Аминокислота выбрана из группы, состоящей из аспарагина, глутаминовой кислоты, глутамина, гистидина, изолейцина, лейцина, лизина, метионина, фенилаланина, серина, треонина, валина, цистеиновой кислоты, N-глицилглицина и орнитина. Предусмотрены также способ доставки никотина в любой форме, способ снижения тяги к курению или использованию табака, а также способ получения указанного покрытого продукта и применение его для получения быстрого всасывания никотина в ротовой полости. Изобретение обеспечивает быстрое всасывание никотина через слизистую оболочку в ротовой полости субъекта. Фармацевтический ...

НЕ СОДЕРЖАЩАЯ ВОЛОКНО ЧРЕСКОЖНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

Изобретение относится к медицине, конкретно к чрескожной терапевтической системе (ЧТС), которая не содержит волокнистые компоненты, и способу изготовления такой чрескожной терапевтической системы, в котором содержащий действующее вещество препарат способом запечатывания наносят на склеивающий при надавливании клейкий слой чрескожной терапевтической системы. ЧТС почти не видимы на коже, поскольку сквозь них виден естественный цвет кожи пользователя. 11 з.п. ф-лы.

НИКОТИНСОДЕРЖАЩАЯ ТАБЛЕТКА И СПОСОБ ЛЕЧЕНИЯ ОТ КУРЕНИЯ

Изобретение относится к области медицины, а именно к наркологии. Таблетка содержит никотин в количестве 0,5 - 5,0 мг, адсорбирующий наполнитель, непитательный подсластитель и целевые добавки. Таблетку вводят буккально и осуществляют контроль содержания никотина в крови на уровне 5 - 50 нг/мл. Способ позволяет повысить эффективность лечения. 2 с. и 21 з.п. ф-лы, 2 табл., 2 ил.

СПОСОБНАЯ ОБРАЗОВЫВАТЬ АЭРОЗОЛЬ КОМПОЗИЦИЯ

Группа изобретений относится к способной образовывать аэрозоль композиции, способу ее изготовления, контейнеру, содержащему эту композицию, а также к устройству, содержащему эту композицию. Способная образовывать аэрозоль композиция содержит: (i) воду в количестве по меньшей мере 30 мас.% по отношению к массе способной образовывать аэрозоль композиции, (ii) никотин в количестве не более чем 6 мас.% по отношению к массе способной образовывать аэрозоль композиции, (iii) по меньшей мере одну кислоту, (iv) одно или несколько вкуcоароматических веществ, (v) один или несколько инкапсулирующих материалов, причем инкапсулирующий материал преимущественно инкапсулирует по меньшей мере одно из указанного одного или нескольких вкуcоароматических веществ, а не протонированный никотин; причем молярное отношение (а) инкапсулирующего материала, инкапсулирующего одно или несколько вкуcоароматических веществ, к (b) неинкапсулированным вкуcоароматическим веществам по меньшей мере в 1,1 раза превышает молярное ...

ПРЕССОВАННАЯ НИКОТИНОВАЯ ПАСТИЛКА

Группа изобретений относится к водорастворимой прессованной пастилке для облегчения тяги к никотину и способу ее производства. Водорастворимая прессованная никотиновая пастилка для перорального применения содержит первый модуль и второй модуль, первый и второй модули соединены обжатием, первый и второй модули образованы множеством спрессованных частиц, первый модуль представляет собой модуль для рассасывания, содержащий по меньшей мере один сахарный спирт в количестве по меньшей мере 50% масс. первого модуля, и второй модуль представляет собой FDT-модуль, содержащий по меньшей мере один сахарный спирт в количестве по меньшей мере 50% масс. второго модуля, и никотин, где второй модуль содержит разрыхлитель, где второй модуль содержит никотин в количестве от 0,2 до 5% масс. второго модуля, где разрыхлитель содержит суперразрыхлитель, где суперразрыхлитель включает сшитые полимеры, где количество суперразрыхлителя составляет от 1 до 14% масс. второго модуля, где первый модуль не содержит никотин ...

Никотинсодержащая съедобная бумага

Изобретение относится к области фармацевтики, а именно к съедобному биоразлагаемому продукту для перорального потребления никотина. Продукт представляет собой съедобную бумагу в виде полоски, пропитанную раствором никотина, его фармацевтически приемлемой соли или его аналога – агониста из группы: цитизин, анабазин, лобелин, при определенном соотношении компонентов раствора и определенном количестве раствора, наносимого на бумагу. Изобретение обеспечивает простоту получения съедобного биоразлагаемого продукта для перорального потребления никотина за счет нанесения на съедобную бумагу заданного количества ингредиентов композиции с никотином или его солью, аналогом, а также обеспечивает оптимизацию дозирования никотина, при которой потребитель может регулировать его поступление путем выбора определенного количества съедобной бумаги, в целях полного отказа от курения или в качестве более безопасной замены курению. 1 з.п. ф-лы, 1 табл., 6 пр.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТАГОНИСТ Р2Х7 РЕЦЕПТОРА И ФАКТОР НЕКРОЗА ОПУХОЛИ

... 1. Фармацевтический продукт, содержащий, в сочетании, препарат первого активного ингредиента, который представляет собой антагонист Р2Х7 рецептора, причем антагонист Р2Х7 рецептора является производным адамантила, и препарат второго активного ингредиента, который представляет собой ингибитор фактора некроза опухоли α (ФНОα), для одновременного, последовательного или раздельного применения в терапии. 2. Композиция по п.1, где антагонист Р2Х7 рецептора представляет собой соединение формулы где m представляет собой 1, 2 или 3; каждый R1a независимо представляет собой атом водорода или галогена; Аa представляет собой C(O)NH или NHC(О); Ara представляет собой группу или Xa представляет собой связь, атом кислорода или группу СО, (CH2)1-6, СН=, (CH2 )1-6O, O(CH2)1-6, O(СН2)2-6О, O(СН2)2-3О(СН2)1-3, CR'(OH), (CH2)1-3О(СН2)1-3, (СН2)1-3О(СН2)2-3О, NR5a, (CH2)1-6NR5a, NR5a(CH2)1-6, (CH2)1-3NR5a(CH2)1-3, O(CH2)2-6NR5a, O(CH2)2-3NR5a(CH2)1-3 , (CH2)1-3NR5a(CH2)2-3O, NR5a(CH2)2-6O, NR5a(CH2)2-3O(CH2 ...

ТВЕРДАЯ НИКОТИНСОДЕРЖАЩАЯ ДОЗИРОВАННАЯ ФОРМА СО СНИЖЕННЫМ НЕПРИЯТНЫМ ОРГАНОЛЕПТИЧЕСКИМ ВОЗДЕЙСТВИЕМ

... 1. Твердая фармацевтическая дозированная форма, содержащая ядро, герметизированное по меньшей мере одним пленочным покрытием, причем ядро содержит никотин и пленочное покрытие содержит по меньшей мере один пленкообразующий полимер и по меньшей мере один компонент для уменьшения одного или более органолептически неприятных ощущений, причем по меньшей мере одно пленочное покрытие не содержит никотин и буферный раствор.2. Дозированная форма по п. 1, где указанное ядро содержит соль цинка или цинковый комплекс.3. Дозированная форма по п. 1, в которой указанное по меньшей мере одно пленочное покрытие предпочтительно имеет толщину от 10 до 500 мкм.4. Дозированная форма по п. 3, в которой указанное по меньшей мере одно пленочное покрытие имеет толщину от 20 до 250 мкм.5. Дозированная форма по п. 3, в которой указанное по меньшей мере одно пленочное покрытие имеет толщину от 30 до 150 мкм.6. Дозированная форма по п. 1, в которой указанное ядро имеет массу от 50 до 2000 мг.7. Дозированная форма ...

СОДЕРЖАЩИЕ ДЕЙСТВУЮЩЕЕ ВЕЩЕСТВО ПЛЕНОЧНЫЕ ПРЕПАРАТЫ С ПОВЫШЕННОЙ ХИМИЧЕСКОЙ СТОЙКОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

... 1. Содержащие действующее вещество пленочные препараты для применения в ротовой полости или через слизистую оболочку, отличающиеся тем, что их переписное число максимально равно 40. 2. Препарат по п.1, отличающийся тем, что его перекисное число максимально равно 15, предпочтительно максимально 5. 3. Препарат по п.1 или п.2, отличающийся тем, что он преимущественно не содержит активный кислород, означающий молекулярный кислород, а также содержащие кислород соединения, в которых окислительное состояние кислорода превышает-2, в особенности, пероксиды с общей структурой R-O-O-R', в которой R и R' означают атомы водорода, либо R означает алкильный остаток, а R' означает атом водорода, либо R и R' означают алкильные остатки, при этом R и R' могут быть идентичны или отличаться друг от друга. 4. Препарат по п.1, отличающийся тем, что он содержит по меньшей мере один антиокислитель, предпочтительно выбранный из группы, включающей аскорбиновую кислоту, аскорбилпальмитат, сульфит натрия, дисульфит ...

ВОДОРАСТВОРИМЫЕ ПЛЕНКИ, СОДЕРЖАЩИЕ МАЛОВЯЗКИЕ АЛЬГИНАТЫ

... 1. Биоадгезивная пленка, содержащая в качестве пленкообразующего агента соль альгиновой кислоты с одновалентным катионом или смесь солей альгиновой кислоты, содержащую, по меньшей мере, одну соль альгиновой кислоты с одновалентным катионом, в которой пленкообразующий агент характеризуется средним содержанием гулуроната (G) от 50 до 85 мас.%, средним содержанием маннуроната (М) от 15 до 50 мас.%, средней молекулярной массой от 30000 до 90000 г/моль, а его 10%-ный водный раствор при температуре 20°С характеризуется вязкостью 100-1000 мПа-с согласно измерению, проведенному при скорости сдвига 20 об/мин с использованием вискозиметра Брукфильда со шпинделем №2. ! 2. Пленка по п.1, в которой одновалентный катион выбирают из Na+, К+ и NH4 +. ! 3. Пленка по п.1, в которой соль альгиновой кислоты с одновалентным катионом содержит от 25 до 35 мас.% β-D-маннуроната. ! 4. Пленка по п.1, в которой соль альгиновой кислоты с одновалентным катионом содержит от 65 до 75 мас.% α-D-гулуроната. ! 5. Пленка ...

СИСТЕМА ТРАНСДЕРМАЛЬНОЙ ДОСТАВКИ НИКОТИНА

... 1. Система трансдермальной доставки никотина, содержащая адгезивный слой, содержащий никотин в форме свободного основания и жидкий ингредиент, совместимый с этим адгезивом, причем адгезивный слой является сшитым, а жидкий ингредиент содержится в пропорции 20-75 вес.ч. на 100 вес.ч. адгезивного слоя в целом. 2. Система по п.1, в которой упомянутый жидкий ингредиент представляет собой сложный алкиловый эфир жирной кислоты и/или глицериновый сложный эфир жирной кислоты.

НЕ СОДЕРЖАЩАЯ ВОЛОКНО ЧРЕСКОЖНАЯ ТЕРАПЕВТИЧЕСКАЯ СИСТЕМА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

... 1. Способ изготовления чрескожной терапевтической системы, отличающийся тем, что ! непроницаемый для действующего вещества несущий слой или необязательно присутствующий резервуарный слой или матричный слой снабжают не содержащим волокно склеивающим при надавливании клейким слоем, ! на склеивающий при надавливании клейкий слой способом запечатывания наносят разделенные на индивидуальные дозы части текучего содержащего действующее вещество препарата, при этом упомянутый текучий содержащий действующее вещество препарат содержит полимер, также являющийся компонентом склеивающего при надавливании клейкого слоя, и ! на последующей стадии на склеивающий при надавливании клейкий слой, снабженный содержащим действующее вещество препаратом, наносят непроницаемый для действующего вещества не содержащий волокно задний слой, ! при этом ЧТС может быть выделена из полученного к тому времени слоистого композита путем резки и/или перфорирования до или после нанесения содержащего действующее вещества препарата ...

УСТРОЙСТВА ДЛЯ ИСПАРЕНИЯ И ИНГАЛЯЦИИ НИКОТИНА

КОМБИНАЦИЯ ТЕТРАПЕПТИДА И ЭФИРА ГЛИЦЕРИНА ДЛЯ ЛЕЧЕНИЯ АНДРОГЕННОЙ АЛОПЕЦИИ

ИНГАЛЯТОР С РЕГУЛИРОВАНИЕМ ПОТОКА

НИКОТИНОВЫЕ СОСТАВЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

МАТЕРИАЛ В ВИДЕ ЧАСТИЦ ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИНГРЕДИЕНТОВ

... 1. Материал в виде частиц для контролируемого высвобождения активных ингредиентов, при этом материал в виде частиц содержит комбинацию одного или более активных ингредиентов, за исключением никотина, и неорганический минеральный наполнитель, причем этот активный ингредиент обратимо абсорбирован в и/или на этом неорганическом минеральном наполнителе, при этом удельная площадь поверхности БЭТ этого неорганического минерального наполнителя составляет более 15 м/г при измерении удельной площади поверхности БЭТ по стандарту ISO 9277.2. Материал по п.1, в котором этим активным ингредиентом является ароматизатор.3. Материал по п.1 или 2, в котором этот неорганический минеральный наполнитель содержит карбонат.4. Материал по п.1 или 2, в котором средний диаметр этого неорганического минерального наполнителя находится в диапазоне между 50 и 0,1 мкм.5. Материал по п.1 или 2, в котором масса высушенного неорганического минерального наполнителя увеличивается по меньшей мере на 1 вес.% при относительной ...

ВОДНАЯ СИСТЕМА ДОСТАВКИ ЛЕКАРСТВ, СОДЕРЖАЩАЯ МАСКИРУЮЩИЙ ВКУС АГЕНТ

... 1. Устойчивая в воде фармацевтическая композиция, содержащая:терапевтический агент имаскирующий вкус агент, включающий циклический олигосахаридв устойчивой в воде фармацевтически приемлемой гелевой матрице,причем устойчивая в воде фармацевтически приемлемая гелевая матрица представляет собой неионспецифичный гель, включающий полисахарид.2. Устойчивая в воде фармацевтическая композиция по п.1, отличающаяся тем, что терапевтический агент является водочувствительным.3. Устойчивая в воде фармацевтическая композиция по п.1, отличающаяся тем, что полисахарид представляет собой геллан.4. Устойчивая в воде фармацевтическая композиция по п.3, отличающаяся тем, что циклический олигосахарид представляет собой циклодекстрин.5. Устойчивая в воде фармацевтическая композиция по п.4, отличающаяся тем, что циклодекстрин включает альфа-, бета- или гамма-циклодекстрин, или его производное или смесь на их основе.6. Устойчивая в воде фармацевтическая композиция по п.5, отличающаяся тем, что циклодекстрин включает ...

5-(3,4-ДИХЛОРФЕНИЛ)-N-(2-ГИДРОКСИЦИКЛОГЕКСИЛ)-6-(2,2,2-ТРИФТОРЭТОКСИ)НИКОТИНАМИД И ЕГО СОЛИ В КАЧЕСТВЕ СРЕДСТВ, ПОВЫШАЮЩИХ КОНЦЕНТРАЦИЮ ЛВП ХОЛЕСТЕРИНА

... 1. Соединение формулыи его изомерные формы и фармацевтически приемлемые соли.2. Соединение формулы I по п.1, которое представляет собой 5-(3,4-дихлорфенил)-N-((1R,2R)-2-гидроксициклогексил)-6-(2,2,2-трифторэтокси)-никотинамид.3. Соединение формулы I по п.1, которое представляет собой 5-(3,4-дихлорфенил)-N-((1S,2R)-2-гидроксициклогексил)-6-(2,2,2-трифторэтокси)-никотинамид.4. Фармацевтическая композиция, включающая соединение формулы I по любому из пп.1-3 и фармацевтически приемлемый носитель и/или вспомогательное вещество.5. Фармацевтическая композиция по п.4, предназначенная для лечения и/или профилактики заболеваний, которые можно лечить средствами, повышающими концентрацию ЛВП холестерина.6. Соединение формулы I по любому из пп.1-3, предназначенное для применения в качестве лекарственного средства.7. Соединение формулы I по п.6, предназначенное для применения в качестве лекарственного средства для лечения и/или профилактики атеросклероза, заболевания периферических сосудов, дислипидемии ...

СПОСОБ И УСТРОЙСТВО ДЛЯ ИСПАРЕНИЯ И ИНГАЛЯЦИИ ВЫДЕЛЕННЫХ ВЕЩЕСТВ

ДОЗОВЫЙ КАРТРИДЖ ДЛЯ ИНГАЛЯТОРА

ПОДАВЛЕНИЕ НЕЖЕЛАТЕЛЬНЫХ СЕНСОРНЫХ ЭФФЕКТОВ ПОСРЕДСТВОМ СОЕДИНЕНИЯ КАМФАРЫ

... 1. Негорючее средство для размещения в полости рта, содержащее:никотин икамфару, растворенную в неароматизированном масляном носителе,где камфара присутствует в концентрации от приблизительно 600 ч/млн до приблизительно 1300 ч/млн.2. Средство по п.1, представляющее собой лекарственное никотиновое средство.3. Средство по п.1, представляющее собой изделие из бездымного табака.4. Средство по п.3, содержащее совокупность частиц табака, по меньшей мере, частично окруженную покрытием, содержащим растворимый в воде, несшитый компонент и по существу не растворимый в воде, сшитый компонент.5. Средство по п.3, представляющее собой пакетик, содержащий бездымный табак, заключенный в водопроницаемую обертку.6. Средство по п.4, где камфара, растворенная в неароматизированном масляном носителе, размещена в покрытии.7. Средство по п.5, где камфара, растворенная в неароматизированном масляном носителе, размещена в покрытии на водопроницаемой обертке пакетика.8. Средство по п.5, где пакетик имеет, по меньшей ...

КОМПОЗИЦИЯ ДЛЯ ДОСТАВКИ ЛЕКАРСТВ, СОДЕРЖАЩАЯ СИЛИЛЬНЫЕ ПОЛИМЕРЫ

ВДЫХАЕМЫЕ НИКОТИНОВЫЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

НОВЫЕ ПРЕПАРАТЫ И ИХ ПРИМЕНЕНИЕ

... 1. Никотинсодержащая фармацевтическая композиция, отличающаяся тем, что она содержит шоколад в качестве носителя. 2. Никотинсодержащая фармацевтическая композиция по п.1, отличающаяся тем, что она дополнительно содержит один или более чем один забуферивающий агент. 3. Никотинсодержащая фармацевтическая композиция по п.2, отличающаяся тем, что один или более чем один забуферивающий агент выбран из карбонатов, бикарбонатов, фосфатов, глицинатов, ацетатов, глюконатов или глицерофосфатов натрия, калия или аммония, или их смесей. 4. Никотинсодержащая фармацевтическая композиция по любому из пп.1-3, отличающаяся тем, что она дополнительно содержит один или более чем один корригент, такой как мята, кофе, оранж, ваниль и молочный ирис. 5. Никотинсодержащая фармацевтическая композиция по п.1, отличающаяся тем, что ее стандартная доза включает в себя никотин от приблизительно 0,5 мг до приблизительно 10 мг, в виде основания; забуферивающий агент от приблизительно 5 мг до приблизительно 40 мг; носитель ...

НИКОТИНОВЫЙ ГЕЛЬ

Группа изобретений относится к гелевой композиции для генерирования аэрозоля и ее применению. Гелеобразная композиция для генерирования аэрозоля, содержащая: никотин; от 50 вес. % до 80 вес. % глицерина; от 0,2 вес. % до 5 вес. % средства для увеличения вязкости, причем средство для увеличения вязкости содержит ксантановую камедь, карбоксиметилцеллюлозу, микрокристаллическую целлюлозу, метилцеллюлозу, аравийскую камедь, гуаровую камедь, лямбда-каррагинан или крахмал; от 0,2 вес. % до 5 вес. % гелеобразующего средства, обеспечивающего сшивание посредством водородных связей, при этом гелеобразующее средство, обеспечивающее сшивание посредством водородных связей, содержит галактоманнан, желатин, агарозу, конжаковую камедь или агар; от 0,2 вес. % до 5 вес. % гелеобразующего средства, обеспечивающего сшивание посредством ионных связей, причем гелеобразующее средство, обеспечивающее сшивание посредством ионных связей, содержит геллан с низким содержанием ацила, пектин, каппа-каррагинан, йота-каррагинан ...

ARZNEIMITTELZUSAMMENSETZUNG FÜR VERABREICHUNG VON NIKOTIN DURCH DIE NASE

BUPROPION METABOLITE UND VERFAHREN ZUR DEREN SYNTHESE UND VERWENDUNG

TABAKERSATZ.

Nicotin - Corona

Die Erfindung betrifft eine Kombination von mindestens zwei Arzneimitteln zur Verwendung bei der Prävention und/oder Behandlung von Covid-19, wobei sowohl das erste Arzneimittel als auch das zweite Arzneimittel als Wirkstoff Nicotin und/oder ein oder mehrere pharmazeutisch akzeptable Salze davon enthalten und sich die Arzneiform des ersten Arzneimittels von der Arzneiform des zweiten Arzneimittels unterscheidet.

NIKOTINHALTIGES MITTEL

An oral administration capsule with a nicotine-containing, fluid medium. The capsule can be opened by pressing it with the teeth, the amount of nicotine is between 0.1 and 10 mg, the medium contains additives to improve its flavour and consistency and its pH is between 6 and 10. A capsule is thus obtained that can have various uses, especially to reduce addiction to smoking and to control feelings of hunger.

NICOTINE CONTAINING LOZENGE

NICOTINE LOZENGES.

A lozenge which is a substitute for smoking tobacco comprises a lozenge core which contains nicotine and/or a nicotine substitute, and a shell or coating around the lozenge core. The shell or coating may comprise an oral-acting, local analgesic, for example eugenol. Such lozenges are more palatable than known anti-smoking lozenges, and are more stable against humidity and loss of the nicotine or nicotine substitute.

BETEL NUT AND NICOTINE CHEWING GUM

A gum based chewing product, particularly a chewing or bubble gum, containing a synthetic or natural betel nut source, and nicotine. Each gum piece may contain between 1 and 12.6 mg of nicotine. The product may contain taste enhancers such as catechu and lime. A process for the preparation of the gum is also outlined.

Sub-lingual drug delivery system using a neutral oil

A pharmaceutical composition for the sublingual delivery of medicaments comprising a neutral oil and a medicament soluble in said oil, providing that said medicament is not nitroglycerine or an artemesinin as defined therein. Also provided are delivery devices adapted for sublingual delivery of such compositions.

Obesity control formulation

Composition for the reduction of side-effects of dopaminergic agents

A composition utilizing a nicotinic receptor modulator, to reduce or eliminate a side effect associated with dopaminergic agent treatment. The composition is a solid unit dosage form that comprises 6mg or less nicotine and a pharmaceutically acceptable excipient. Preferably the unit dosage form comprises 3mg or less nicotine.

Gum based chewing product and process for preparing the same

An Improved Medicine or Medicinal Preparation or Compound for Animals.

... 10,422. Krahe, J. W. April 29. No Patent granted (Sealing fee not paid). Hypodermic injections for animals consist of mixtures of formalin and nicotine.

Aerosolisable gel

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERAMMONIEMIA

... 1492180 Preparing nicotinohydroxamic acid EISAI CO Ltd 20 Nov 1974 [21 Nov 1973] 50256/74 Heading C2C [Also in Division A5] Nicotinohydroxamic acid is prepared by reacting methyl nicotinate with hydroxylamine hydrochloride. Nicotinohydroxamic acid is used in the treatment of hyperammoniemia (see Division A5).

Supported Nicotine Composition

A premix composition comprising 20-60% calcium silicate and 10-60% nicotine or an equivalent amount of nicotine salt. A method for preparing the premix comprising mixing 20-60% calcium silicate and 10-60% nicotine or an equivalent amount of nicotine salt is also included. The composition may be for use in a tobacco replacement product or for stabilisation of nicotine and may be used orally, preferably as a tablet, lozenge, pill, capsule, chewing gum, troche or pouch, as a patch or as a heat-not-burn composition. The nicotine or nicotine salt may be selected from or formed from synthetic nicotine or nicotine extracted from tobacco. The ratio of nicotine to calcium silicate may be from 5%:95% to 75%:25%. The composition may comprise an acid, ethanol, carbon dioxide or glycerol. The acid may be pyruvic, benzoic, levulinic, citric, gluconic, glucuronic, ribonic, arabinonic or galactonic acid, preferably a hydroxy acid and most preferably citric or gluconic acid. The composition may comprise ...

Method of treatment.

A method for promoting smoking cessation or reduction or preventing relapse smoking, comprises administering an effective, non-toxic amount of paroxetine or a pharmaceutically acceptable salt or solvate thereof, to human in need thereof.

Method of promoting smoking cessation.

Skin-permeable selective cyclooxygenase-2 inhibitor composition.

A dermally deliverable pharmaceutical composition comprises at least one selective cyclooxygenase-2 (COX-2) inhibitory drug or prodrug thereof solubilized in a pharmaceutically acceptable carrier that comprises a low molecular weight mono-hydric alcohol, and exhibits a skin permeation rate of the therapeutic agent at feast equal to that exhibited by a reference solution of the therapeutic agent in 70% aqueous ethanol. A method of effecting targeted delivery of a selective COX-2 inhibitory drug to a site of pain and/or inflammation in a subject comprises topically administering such a composition to skin of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation. A method of effecting systemic treatment of a subject having a COX-2 mediated disorder comprises transdermally administering such a composition, preferably by contacting the composition with an area of skin of the subject not greater than about 400 cm2.

Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol.

Treatment to prevent and look after all types of ignitions like the whitlow abscess or furoncles (l.p.v.)

Method of promoting smoking cessation.

Method of promoting smoking cessation.

Skin-permeable selective cyclooxygenase-2 inhibitor composition.

Method of treatment

MEDICAMENTOUS ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING RUBBER

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

PROCEDURE FOR the PRODUCTION OF 4-ARYLNICOTINAMIDDERIVATEN

WIRKSTOFFHALTIGE FILMFÍRMIGE PREPARATIONS WITH IMPROVE CHEMICAL, AND PROCEDURE FOR THEIR PRODUCTION STABILITAT

NICOTINE ABSTENTION FILM PREPARATION

SMOKELESS TOBACCO PRODUCT

BUPROPION METABOLITES FOR THE TREATMENT OF FEAR CONDITIONS

TRANSPARENT TRANSDERMALE NICOTINE DELIVERY DEVICES

CONNECTIONS TO THE INHIBITION IAPP ASSOCIATING AMYLOID DEPOSIT

USE OF HERB CIGARETTES

DEVICE FOR GIVING MEDICINES ON MUCOUS MEMBRANE FABRICS

TRANSMUKOSALE DOSE FORM

INHALATOR

Die Erfindung betrifft eine Inhalatorkomponente für die Bildung eines nikotinhaltigen Dampf-Luft-Gemisches oder/und Kondensationsaerosols durch Verdampfung einer mittels Ethanol oder/ und Wasser hochverdünnten Nikotinlösung, umfassend:ein Gehäuse (3);eine im Gehäuse (3) angeordnete Kammer (21);eine Lufteinlaßöffnung (26) für die Zufuhr von Luft aus der Umgebung in die Kammer (21);einen Verdampfer (22) zur Verdampfung einer Portion der hochverdünnten Nikotinlösung (16) mit einer in der Kammer (21) angeordneten Verdampfungsfläche bzw. Dampfaustrittsfläche, aus welcher der erzeugte Dampf in die Kammer (21) übertritt und sich in der Kammer (21) mit der durch die Lufteinlaßöffnung (26) zugeführten Luft mischt, wodurch sich schließlich das nikotinhaltige Dampf-Luft-Gemisch oder/und Kondensationsaerosol bildet;einer von einem Mundstück (5) gebildeten Mundstücköffnung, welche mit der Kammer (21) kommuniziert, und durch welche ein Benutzer das nikotinhaltige Dampf-Luft-Gemisch oder/und Kondensationsaerosol ...

INHALATOR

INHALATOR

Die Erfindung betrifft eine Inhalatorkomponente für die intermittierende, inhalations- oder zugsynchrone Bildung eines Dampf-Luft-Gemisches oder/und Kondensationsaerosols, umfassend:ein Gehäuse (3);eine im Gehäuse (3) angeordnete Kammer (21);eine Lufteinlaßöffnung (26) für die Zufuhr von Luft aus der Umgebung in die Kammer (21);ein elektrisches Heizelement zur Verdampfung einer Portion eines flüssigen Materials (16), wobei der gebildete Dampf sich in der Kammer (21) mit der durch die Lufteinlaßöffnung (26) zugeführten Luft mischt, und sich das Dampf-Luft-Gemisch oder/und Kondensationsaerosol bildet;und einen Docht mit einer Kapillarstruktur, welcher Docht mit dem Heizelement einen Verbund (22) bildet und das Heizelement nach einer Verdampfung von neuem selbsttätig mit dem flüssigen Material (16) versorgt.Um die für einen intermittierenden, inhalations- oder zugsynchronen Betrieb der Inhalatorkomponente (2) erforderliche hohe spezifische Verdampfungsleistung bei gleichzeitig hohem Verdampfer-Wirkungsgrad ...

TOBACCO REPLACEMENT.

TRANSDERMALE APPLICATION OF NICOTINE.

COMPOSITIONS AND PROCEDURES FOR THE PRODUCTION OF CURES ZERSETZLICHEN IN THE MOUTH

FORMULATIONS AND PROCEDURES FOR AN EXTENDED LOCAL ANAESTHESIA

TRANSDERMALE OR TRANSMUCOSALE DARREICHUNGSFORMEN WITH A NICOTINHALTIGEN ACTIVE SUBSTANCE COMBINATION TO THE SMOKER CURING

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISTURBANCES OF THE CENTRAL NERVOUS SYSTEM WHICH ONE NICOTINE SIMILAR TO AND AN ACETYLCHOLINESTERASE AN INHIBITOR CONTAINING

CHEMICALLY AND PHYSICAL STABLE TEILCHENFÖRMIGES MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE

Chewing Gum And Particulate Material For Controlled Release Of Active Ingredients

A particulate material for controlled release of active ingredients includes a combination of one or more active ingredients, including nicotine, and an inorganic mineral filler, in which the active ingredient is reversibly absorbed into and/or adsorbed onto the inorganic mineral filler, and the BET specific surface area of the inorganic mineral filler is above 15 m 2 /g, the BET specific surface area measured in accordance with ISO 9277. Further, a chewing gum having the particulate material includes a combination of one or more active ingredients, such as nicotine or a flavoring agent, and an inorganic mineral filler. Finally, the method of producing the chewing gum is provided. The invention is particularly advantageous for controlled release of active ingredients.

Inhibition of undesired sensory effects by the compound camphor

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Therapeutic uses of nicotine

The uses of nicotine, analogues, precursors or derivatives thereof for treatment of inflammatory, infectious, candidal or degenerative diseases of the joint, central nervous system, kidney, lung, and liver, depression, obesity, bone disease and the like are described. The various diseases, disorders or conditions can be improved by means of intensification of the actions of α-MSH, whose release is affected by the use of nicotine, analogues, precursors or derivatives thereof, which can increase and/or reduce the bioavailability of α-MSH in blood and/or central or peripheral tissues to accentuate or diminish the effect of the α-MSH for therapeutic and/or prophylactic purposes.

Chewing gum having sustained release of nicotine

The present invention relates to a chewing gum having a high Surface Area to Volume ratio (SAV ratio), wherein said chewing gum comprises a water insoluble gum base matrix, a water soluble bulk portion and nicotine, wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1-10% of C8-C10 triglycerides by weight of the chewing gum.

Melt extruded nicotine thin strips

A thin strip for oral ingestion is between 0.05 millimeters and 2.00 millimeters thick. It includes 10 to 80% by weight of polyethylene oxide having a molecular weight of from 70,000 to 300,000 daltons. It further includes 5 to 50% by weight of a sugar alcohol having a melting point in excess of 75 C and 5 to 30% by weight of polyethylene glycol having a molecular weight of from 200 to 1,000 daltons. Lastly it includes 1 to 30% by weight of a carboxy vinyl polymer cross linked with an allyl ether of pentaerythritol, and 1 to 10% by weight of an organic acid addition salt of nicotine.

Oral dosage forms

The invention relates to specific three layer dosage forms for oral administration of pharmaceutical active substances.

FORMULATION COMPRISING NICOTINE AND A CATION EXCHANGE RESIN

A method of producing a nicotine delivery product includes a mixture having nicotine, a cation exchange resin and water. The water content of the mixture is between 5 and 75 wt. % relative to the whole mixture. The mixture is combined with further components of the nicotine delivery product. 1. A method of producing a nicotine delivery product , the method comprising: combining (i) a mixture comprising nicotine , a cation exchange resin and water , wherein the water content of the mixture is between 5 and 75 wt. % relative to the whole mixture; and (ii) further components of the nicotine delivery product.2. The method according to claim 1 , wherein the nicotine delivery product is selected from nicotine-containing chewing gums claim 1 , nicotine-containing lozenges claim 1 , nicotine-containing pastilles claim 1 , nicotine-containing tablets claim 1 , nicotine-containing patches claim 1 , nicotine-containing inhalers and nicotine-containing nasal sprays.32. The method according to any of - wherein the water content of the mixture is between 10 and 75 wt. % claims 1 , such as between 15 and 65 wt. % claims 1 , such as between 20 and 55 wt. % claims 1 , such as between 25 and 45 wt. %.43. The method according to any of - wherein the cation exchange resin is selected from the group consisting of (i) a methacrylic claims 1 , weakly acidic type of resin containing carboxylic functional groups such as polacrilex (Amberlite® IRP64) (ii) a polystyrene claims 1 , strongly acidic type of resin containing sulphonic functional groups claims 1 , and (iii) a polystyrene claims 1 , intermediate acidic type of resin containing phosphonic functional groups.54. The method according to any of - claims 1 , wherein the concentration of nicotine in the mixture is between 5 and 50 wt. %.65. The method according to any of - claims 1 , wherein the weight ratio of cation exchange resin to nicotine in the mixture is from 1:1 to 10:1.76. The method according to any of - claims 1 , wherein the ...

INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL

A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight, 2. A method as claimed in claim 1 , wherein the KMUPS compound comprising is one selected from a group consisting of KMUP-1 claim 1 , KMUP-2 claim 1 , KMUP-3 and KMUP-4.3. A method as claimed in claim 2 , wherein KMUP-1 is 7-[2-[4-(2-chlorobenzene) piperazinyl]ethyl]-1 claim 2 ,3-dimethylxanthine claim 2 , KMUP-2 is 7-[2-[4-(2-methoxybenzene)piperazinyl]ethyl]-1 claim 2 ,3-dimethylxanthine claim 2 , KMUP-3 is 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1 claim 2 ,3-dimethylxanthine and KMUP-4 is 7-[2-[4-(2-nitrobenzene)piperazinyl]ethyl]-1 claim 2 ,3-dimethylxanthine.4. A method as claimed in claim 1 , wherein the pulmonary inflammation comprising one selected from a group consisting of an obstructive pulmonary disease claim 1 , a pulmonary artery hypertension claim 1 , pulmonary artery proliferation claim 1 , an allergic pulmonary vascular inflammation claim 1 , a physiological activity of a lung cell claim 1 , a vascular remodeling inhibiting disease and a combination thereof.5. A method as claimed in claim 1 , wherein the administering steps is performed by an oral administration.7. A method as claimed in claim 6 , wherein the KMUPS complex compound is one selected from a group consisting of KMUP-1-Atorvastatin complex claim 6 , KMUP-2-Atorvastatin complex claim 6 , KMUP-3-Atorvastatin complex claim 6 , KMUP-4-Atorvastatin complex claim 6 , KMUP-1-Cerivastatin complex claim 6 , KMUP-2-Cerivastatin complex claim 6 , KMUP-3-Cerivastatin complex claim 6 , KMUP-4-Cerivastatin complex; KMUP-1-Fluvastatin complex claim 6 , KMUP-2-Fluvastatin complex claim 6 , KMUP-3-Fluvastatin complex claim 6 , KMUP ...

Method for the preparation of cis-1,2-diols in the kilogram scale

The present invention relates to the scale up of the preparation of cis-1,2-diols of formula I from the gram to the kilogram scale.

REMEDY FOR MIGRAINE HEADACHE

A medicated formulation and method of use for treating migraine having a combination of active ingredients including: nicotine, and tryptophan alone and also with phenylalanine and/or, tyrosine, and/or caffeine in an aqueous solution. 1. A medication formulation for treating migraine comprising an aqueous solution containing active ingredients including an effective amount of: nicotine , tryptophan , phenylalanine , tyrosine and caffeine , wherein the nicotine comprises not less than 0.222 mg.2. A medication formulation for treating migraine comprising an aqueous solution containing active ingredients including an effective amount of: nicotine and tryptophan , wherein the nicotine comprises not less than 0.222 mg.3. The medication formulation for treating migraine of claim 2 , further comprising an effective amount of phenylalanine.4. The medication formulation for treating migraine of claim 3 , further comprising an effective amount of tyrosine.5. The medication formulation for treating migraine of claim 4 , further comprising an effective amount of caffeine.6. The medication formulation for treating migraine of claim 1 , wherein the solution contains 0.222 mg nicotine claim 1 , 40 mg tryptophan claim 1 , 20 mg phenylalanine claim 1 , 60 mg tyrosine claim 1 , and 85 mg caffeine in two liquid ounces of water.7. The medicated formulation of wherein the nicotine represents about 0.11% by weight of the active ingredients.8. The medicated formulation of wherein the tryptophan represents between 15 and 30% by weight of the active ingredients.9. The medicated formulation of wherein the phenylalanine represents between 5 and 15% by weight of the active ingredients.10. The medicated formulation of wherein the tyrosine represents between 20 and 30% by weight of the active ingredients.11. The medicated formulation of wherein the caffeine represents between 35 and 50% by weight of the active ingredients.12. The medicated formulation of wherein the active ingredients are by ...

Snuff composition

Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Compositions Comprising Nicotinic Agonists and Methods of Using Same

The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol). 1. A method for treatment of a central nervous system (CNS) or a peripheral nervous system disorder , comprising co-administering to a patient in need thereof a therapeutically effective amount of a nicotinic agonist and a nicotinic acetylcholine receptor (nAChR) desensitization inhibitor.2. The method of claim 1 , wherein said CNS disorder is a cognitive disorder.3. The method of claim 1 , wherein said CNS disorder is selected from the group consisting of Alzheimer's disease claim 1 , Parkinson's disease claim 1 , schizophrenia claim 1 , attention deficit hyperactivity disorder (ADHD) claim 1 , attention deficit disorder (ADD) claim 1 , vascular dementia claim 1 , Lewy body disease claim 1 , post-traumatic dementia claim 1 , Pick's disease claim 1 , multiple sclerosis claim 1 , Jakob-Creutzfeldt disease claim 1 , nicotine addiction claim 1 , alcohol addiction claim 1 , cannabis addiction claim 1 , cocaine addiction claim 1 , neurological conditions associated with acquired immune deficiency syndrome (AIDS) claim 1 , and Huntington's disease.47-. (canceled)8. The method of claim 1 , wherein the effect of nicotinic agonist after co-administration is about twice as effective as compared to administering to the patient the nicotinic agonist alone.9. (canceled)10. The method of claim 1 , wherein the nAChR desensitization inhibitor reduces the desensitization of said nicotinic agonist for at least about 12 hours.1112-. (canceled)13. The method of claim 1 , wherein the nicotinic agonist and the nAChR desensitization inhibitor are administered together in the same dosage form.14. The method of claim 1 , wherein the nicotinic agonist and the ...

High enhancer-loading polyacrylate formulation for transdermal applications

A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

NEUROPROTECTION BY PHARMACOLOGICAL CHAPERONING OF NICOTINIC ACETYLCHOLINE RECEPTORS

A method of ameliorating an endoplasmic reticulum (ER) stress response and/or unfolded protein response (UPR) in cells expressing nicotinic acetylcholine receptors (nAChRs) comprises contacting a cell expressing nAChRs with an effective amount of a ligand for nAChRs. The contacting results in attenuating endogenously expressed ATF6 translocation, expression of XBP1, phosphorylation of eukaryotic initiation factor 2α (peIF2α), increased numbers of ER exit sites, increased trafficking of known associated proteins as well as other proteins such as growth factors and their receptors, changes in abundance of selected mRNA species, and phosphorylation, abundance, or subcellular compartmentalization of other proteins involved with ER stress and/or the UPR, and inhibiting upregulation of CCAAT/Enhancer-Binding Protein Homologous Protein (CHOP) levels in the cells. The method can be used to screen for neuropharmacotherapeutic agents and to treat or prevent neurodegenerative disease, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, or cognitive deficiency. 1. A method of ameliorating an endoplasmic reticulum (ER) stress response in cells expressing nicotinic acetylcholine receptors (nAChRs) , the method comprising contacting cells expressing nAChRs with an effective amount of a ligand for nAChRs.2. The method of claim 1 , wherein the contacting results in attenuating endogenously expressed ATF6 translocation claim 1 , expression of XBP1 claim 1 , phosphorylation of eukaryotic initiation factor 2α (peIF2α) claim 1 , increased numbers of ER exit sites claim 1 , and/or inhibits upregulation of CCAAT/Enhancer-Binding Protein Homologous Protein (CHOP) levels in the cells.3. The method of claim 1 , wherein the cells are central nervous system (CNS) neurons.4. The method of claim 3 , wherein the neurons are thalamic claim 3 , cortical claim 3 , habenular claim 3 , substantia nigra (SN) or motor neurons.5. The method of claim 1 , wherein the ...

Toffee Gum Comprising Chocolate

The invention relates to toffee gum comprising a polymer system, and at least 1% by weight of chocolate, said polymer system constituting at least 10% by weight of said toffee gum, at least 70% by weight of said polymer system comprising polyvinyl acetate, said polyvinyl acetate having a glass transition temperature (T g ) in the range of 0 to 60° C., and said chocolate constituting at the most 90% by weight of said toffee gum.

Formulation and Use and Manufacture Thereof

This invention relates to a liquid pharmaceutical formulation for delivering nicotine to a subject. This invention also relates to a method and a system for delivering nicotine as well as manufacturing and use of said liquid pharmaceutical formulation. 1. A liquid pharmaceutical formulation for use in the treatment of addiction to tobacco or nicotine , comprising:(i) nicotine in free nicotine base form; and(ii) a buffering agent,(iii) the liquid pharmaceutical formulation being adapted for administration to the oral cavity of a subject by spraying, dropping or pipetting, and{'sub': 'max', '(iv) the liquid pharmaceutical formulation being adapted so as to achieve a tof nicotine in venous blood of the subject within from about 3 to about 30 minutes after an incidence of administration of the liquid pharmaceutical formulation.'}2. The liquid pharmaceutical formulation of claim 1 , wherein the buffering agent comprises a carbonate claim 1 , a glycinate claim 1 , a phosphate claim 1 , a glycerophosphate claim 1 , an acetate claim 1 , a gluconate claim 1 , or citrate of an alkali metal claim 1 , or any combination thereof.3. The liquid pharmaceutical composition of claim 1 , further comprising a pH regulating agent.4. The liquid pharmaceutical composition of claim 3 , wherein the pH regulating agent comprises sodium hydroxide claim 3 , potassium hydroxide claim 3 , calcium hydroxide claim 3 , or calcium oxide.5. The liquid pharmaceutical formulation of claim 1 , wherein the liquid phase comprises an alcohol.6. The liquid pharmaceutical formulation of claim 1 , wherein the liquid phase comprises one or more lipids.7. The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation comprises water claim 1 , an alcohol claim 1 , a lipid claim 1 , or any combination thereof.8. The liquid pharmaceutical formulation of claim 1 , further comprising a flavor agent.9. The liquid pharmaceutical formulation of claim 1 , further comprising an ...

NEW PRODUCT

The invention relates to a nicotine oral delivery product containing a powder enclosed in a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said powder comprising at least 1. A nicotine oral delivery product containing a powder enclosed in a water insoluble pouch , wherein said pouch is permeable for saliva and therein dissolved parts of the powder , wherein said powder comprising at leasta) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base andb) a chewing gum composition.2. The product according to claim 1 , wherein said nicotine is tobacco or nicotine salt claim 1 , and mixtures thereof.3. The product according to claim 2 , wherein said nicotine salt is selected from the group consisting of nicotine hydrochloride claim 2 , nicotine dihydrochloride claim 2 , nicotine monotartrate claim 2 , nicotine bitartrate claim 2 , nicotine bitartrate dihydrate claim 2 , nicotine sulphate claim 2 , nicotine zinc chloride monohydrate and nicotine salicylate claim 2 , and mixtures thereof.4. The product according to claim 3 , wherein said nicotine salt is nicotine bitartrate dihydrate.5. The product according to claim 1 , wherein said nicotine is nicotine base.6. The product according to claim 1 , wherein said nicotine is stabilized nicotine.7. The product according to claim 1 , wherein said product comprises nicotine selected from the group consisting of tobacco claim 1 , nicotine salts claim 1 , nicotine base claim 1 , stabilized nicotine claim 1 , and mixtures thereof in an amount from 0.1 to 10 mg per product calculated as nicotine in the form of nicotine base.8. The product according to claim 7 , wherein said product comprises nicotine selected from the group consisting of tobacco claim 7 , nicotine salts claim 7 , nicotine base claim 7 , stabilized nicotine ...

Remelted ingestible products

A method of preparing an orally ingestible hard boiled product, comprising: i) heating a sugar material to a first temperature sufficient to liquefy the sugar material; ii) cooling the liquefied sugar material to provide a cooled sugar material having a solid or semi-solid form; iii) heating the cooled sugar material to a second temperature, which is lower than the first temperature; iv) combining the sugar material with one or more temperature sensitive ingredients before, during, or after said heating step iii), but after said cooling step ii), such that an intimate mixture of the second liquefied sugar material and the one or more temperature sensitive ingredients is provided; and v) cooling the intimate mixture to form an orally ingestible product. Orally ingestible hard boiled products prepared according to this method are also provided.

Tobacco Alkaloid Releasing Chewing Gum

The invention relates to a tobacco alkaloid releasing chewing gum comprising tobacco alkaloid, gum base, and chewing gum ingredients, said gum base comprising elastomer and resin-compounds constituting an amount in the range of about 2 to 20% by weight of said chewing gum. 1. Tobacco alkaloid releasing chewing gum comprising tobacco alkaloid , gum base , and chewing gum ingredients , said gum base comprising elastomer- and resin-compounds constituting an amount in the range of about 2 to 20% by weight of said chewing gum.2. Tobacco alkaloid releasing chewing gum according to claim 1 , wherein said chewing gum comprises tobacco alkaloid in an amount of 0.1 mg to 10 mg.3. Tobacco alkaloid releasing chewing gum according to claim 1 , wherein said chewing gum comprises tobacco alkaloid in an amount of 0.1 mg to 10 mg in the gum base of the chewing gum.4. Tobacco alkaloid releasing chewing gum according to claim 1 , wherein said tobacco alkaloid is in a form selected from tobacco alkaloid salts claim 1 , tobacco alkaloid bound in a complex claim 1 , or any combination thereof.5. Tobacco alkaloid releasing chewing gum according to claim 1 , wherein said tobacco alkaloid is nicotine.6. Tobacco alkaloid releasing chewing gum according to claim 5 , wherein said nicotine is in a form selected from nicotine salts claim 5 , nicotine free base claim 5 , nicotine bound in a complex claim 5 , or any combination thereof.7. Tobacco alkaloid releasing chewing gum according to claim 4 , wherein said complex comprises an ion exchange resin.8. Tobacco alkaloid releasing chewing gum according to claim 7 , wherein said ion exchange resin is a weakly acidic cation exchange resin.9. Tobacco alkaloid releasing chewing gum according to claim 4 , wherein said complex comprises an adsorbent.10. Tobacco alkaloid releasing chewing gum according to claim 9 , wherein said adsorbent is selected from the group consisting of finely divided silicic acid claim 9 , amorphous silica claim 9 , magnesium ...

Method Of Providing Fast Relief To A User Of A Nicotine Chewing Gum

The invention relates to a method of relieving nicotine craving comprising the steps of providing at least one chewing gum comprising tobacco alkaloid to a user, providing relief of nicotine craving to said user by transferring of tobacco alkaloid from the chewing gum to the human body of said user by chewing of said chewing gum, said chewing of said chewing gum comprising a chewing process involving a transfer of tobacco alkaloid from said chewing gum above a threshold transfer rate in the period of about ½ minute to about 2½ minutes from initiation of said chewing process. 1. Method of relieving nicotine craving comprising the steps of providing at least one chewing gum comprising tobacco alkaloid to a user , providing relief of nicotine craving to said user by transferring of tobacco alkaloid from the chewing gum to the human body of said user by chewing of said chewing gum , said chewing of said chewing gum comprising a chewing process involving a transfer of tobacco alkaloid from said chewing gum above a threshold transfer rate in the period of about ½ minute to about 2½ minutes from initiation of said chewing process.2. Method of relieving nicotine craving according to claim 1 , wherein said tobacco alkaloid comprises nicotine.3. Method of relieving nicotine craving according to claim 1 , wherein said transfer rate refer to a transfer of nicotine from the chewing gum to the exterior of the chewing gum.4. Method of relieving nicotine craving according to claim 1 , wherein said threshold transfer rate is evaluated in sub periods of the period of about ½ minute to about 2½ minutes from initiation of said chewing process.5. Method of relieving nicotine craving according to claim 1 , wherein said chewing of said chewing gum comprising a chewing process involving a transfer of tobacco alkaloid from said chewing gum above a further threshold transfer rate in the period of about 2½ minutes to about 10 minutes from initiation of said chewing process erably in the ...

Method of identifying and treating a person having a predisposition to or afflicted with Parkinson disease

The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual. 1. A method of treating or inhibiting the development of Parkinson's Disease in a person in need thereof , comprising providing individualized or personalized treatment comprising:(a) analyzing DNA from a blood, saliva or tissue sample obtained from the person;(b) determining from said analyzing the presence of a polymorphic site in a genetic locus, whereby the presence of the polymorphic site identifies a gene variant that allows or increases the neuroprotective effect of (i) nicotine (ii) caffeine or (iii) NSAID consumption; and(c) if the polymorphic site is present and (i) the presence of the polymorphic site identifies a gene variant that allows or increases the neuroprotective effect of nicotine, then administering to the person a medicament comprising nicotine or a nicotine analog, or (ii) the presence of the polymorphic site identifies a gene variant that allows or increases the neuroprotective effect of caffeine, then administering to the person a medicament comprising caffeine or a caffeine analog, or (iii) the presence of the polymorphic site ...

Sedative for use during eye surgery

A drug for sedating a patient, and especially a smoker, during eye surgery. The drug includes a sedative such as midazolam in a mix with nicotine. The mixture is injected into the patient prior to the eye surgery.

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PHENYLKETONURIA (PKU)

A method of diagnosing Phenylketonuria (PKU) in a subject in need thereof is disclosed. The method comprises detecting phenylalanine fibrils in a tissue of the subject, wherein a presence or level above a predetermined threshold of said phenylalanine fibrils in said tissue, is indicative of PKU in the subject. Antibodies capable of detecting phenylalanine fibrils are also disclosed as well as additional uses. 1. A method of diagnosing Phenylketonuria (PKU) in a subject in need thereof , the method comprising detecting phenylalanine fibrils in a tissue of the subject , wherein a presence or level above a predetermined threshold of said phenylalanine fibrils in said tissue , is indicative of PKU in the subject.2. The method of claim 1 , wherein said detecting is effected using an isolated antibody which specifically binds to fibrils consisting of phenylalanine.3. The method of claim 1 , wherein said detecting is effected with a dye.4. The method of claim 3 , wherein said dye is selected from the group consisting of Congo red and ThT.5. An isolated antibody which specifically binds to fibrils consisting of phenylalanine.6. The isolated antibody of claim 5 , attached to an identifiable moiety.7. The isolated antibody of claim 5 , being a polyclonal antibody.8. The isolated antibody of claim 5 , being a monoclonal antibody.9. A pharmaceutical composition comprising as an active ingredient the isolated antibody of .10. A method of detecting phenylalanine fibrils in a biological sample claim 5 , the method comprising contacting the biological sample with the antibody of under conditions which allow formation of immunocomplexes claim 5 , wherein a presence of immunocomplexes above a predetermined threshold is indicative of phenylalanine fibrils in the biological sample.11. A method of treating PKU in a subject in need thereof claim 5 , the method comprising administering to the subject a therapeutic effective amount of an anti-amyloid agent claim 5 , thereby treating the ...

POUCH CONTAINING NICOTINE IN FREE SALT FORM

The invention relates to a product for oral delivery of nicotine containing a core comprising a powder of at least one free nicotine salt, at least one pH adjusting agent and at least one filler, and a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said product upon contact with purified water gives a pH of at least 6. The invention also relates to a method to manufacture such a product. 2. The product according to claim 1 , wherein said nicotine salt is water soluble.3. The product according to claim 1 , wherein said nicotine salt is selected from the group consisting of nicotine hydrochloride claim 1 , nicotine dihydrochloride claim 1 , nicotine monotartrate claim 1 , nicotine bitartrate claim 1 , nicotine bitartrate dihydrate claim 1 , nicotine sulphate claim 1 , nicotine zinc chloride monohydrate and nicotine salicylate claim 1 , and mixtures thereof.4. The product according to claim 3 , wherein said nicotine salt is nicotine bitartrate dihydrate.5. The product according to claim 1 , wherein said pH adjusting agent is selected from the group consisting of carbonates including monocarbonate claim 1 , bicarbonate and sesquicarbonate claim 1 , acetates claim 1 , glycinates claim 1 , gluconates claim 1 , borates claim 1 , glycerophosphates or citrates of alkaline metals or ammonium claim 1 , phosphate systems including monohydrogenphosphate claim 1 , dihydrogenphosphate and trihydrogenphosphate claim 1 , metal hydroxides such as sodium hydroxide and potassium hydroxide claim 1 , and mixtures thereof.6. The product according to claim 5 , wherein said pH adjusting agent is sodium bicarbonate or sodium carbonate claim 5 , and mixtures thereof.7. The product according to claim 5 , wherein said pH adjusting agent is encapsulated or embedded.8. The product according to claim 7 , wherein said pH adjusting agent is encapsulated or embedded with a polymer which physically separates the pH adjusting agent ...

Infused Carbohydrate Based Gel Pad for Sustained Oral Transmucosal Delivery

The present invention provides an infused carbohydrate based gel pad comprising: glucose polymer syrup, sugar, a hydrocolloid gelling agent, salt, acid, water and an infusing compound for oral transmucosal delivery wherein the gel pad (i) provides transmucosal delivery of active ingredients of the infusing compound into the bloodstream over a predetermined period of time; and (ii) possesses the property of adhesion to gum line tissue of an oral cavity and lack of adhesion to buccal tissue of the oral cavity. The present invention further provides a method of making the infused carbohydrate based gel. 1. An infused carbohydrate based gel pad comprising: glucose polymer syrup , sugar , a hydrocolloid gelling agent , salt , acid , water and an infusing compound for oral transmucosal delivery wherein the gel pad (i) provides transmucosal delivery of active ingredients of the infusing compound into the bloodstream over a predetermined period of time; and (ii) possesses the property of adhesion to gum line tissue of an oral cavity for transmucosal delivery of the active ingredients across buccal tissue of the oral cavity into the bloodstream.2. The gel pad of wherein the gel pad is made from the following formulation of ingredients: the glucose polymer syrup at a concentration ranging from about 40% to about 60%; the sugar at a concentration ranging from about 25% to about 45%; the hydrocolloid agent at a concentration ranging from about 1% to about 4%; the salt at a concentration ranging from about 1% to about 7%: the acid at a concentration ranging from about 0.5% to about 3.0%; the water at a concentration ranging from about 8% to about 25% wherein concentrations of the ingredients are all measured based upon total weight of the formulation.3. The gel pad of wherein the glucose polymer syrup is selected from the group consisting of sucrose syrup claim 1 , brown rice syrup claim 1 , white rice syrup claim 1 , tapioca syrup claim 1 , high fructose corn syrup claim 1 , ...

Nutritional supplement for disinhibiting therapy of psychiatric patients

The present invention is a composition and methods of administering the composition to improve a person's mental and physical health by increasing energy levels, motivation, willingness to communicate, appetite, and memory. The composition may be used to treat mental conditions by improving a person's wiliness and ability to communicate. The increase in appetite effect of the composition may be used to treat eating disorders. The composition comprises a carbohydrate, one or more NAD+/NADP+ producing vitamins, poly-sulfurous chelating agents, vasodilating salts, coenzyme-A producing vitamins, antioxidants, kinins, and biological energy sources. 1. A mixture to alleviate conditions that are characterized by low energy , fatigue , exhaustion , or lack of concentration , comprising at least one carbohydrate , one or more water-soluble NAD+/NADP+ providing vitamins , one or more organic phosphates or its precursors , one or more metal chelating agents , one or more vasodilating agents , one or more antioxidants , and one or more kinins.2. A method of treating a neurological or psychological condition comprising administering the mixture of to a patient suffering from said neurological or physiological condition.3. The method of 2 wherein the neurological or psychological condition is ADHD claim 1 , autism claim 1 , catatonia claim 1 , anorexia claim 1 , depression claim 1 , schizophrenia claim 1 , neurasthenia claim 1 , chronic fatigue syndrome claim 1 , psychosis or closed head trauma.4. A method of treating a physiological condition comprising administering the mixture of to the patient suffering from said physiological condition.5. The method of wherein the physiological condition is HIV/AIDS infection claim 4 , atherosclerosis claim 4 , cold infection claim 4 , influenza infection claim 4 , or endocrine dissorder.6. A method to treat conditions related to dysfunction of tissues and organs due to disorders of blood circulation comprising administering the mixture of ...

COMPLEX IN WHICH ANTI-COTININE ANTIBODY IS BOUND TO CONJUGATE OF COTININE AND BINDING SUBSTANCE, AND USE THEREOF

The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody. 1. A complex in which an anti-cotinine antibody is bound to a conjugate of cotinine and a binding material.2. The complex of claim 1 , wherein the binding material is selected from the group consisting of a peptide claim 1 , an aptamer claim 1 , a hormone claim 1 , a protein and a chemical material.3. The complex of claim 1 , wherein the binding material is selected from the group consisting of WKYMVm-NHpeptide claim 1 , AS1411 aptamer claim 1 , pegaptanib claim 1 , abciximab and insulin.4. The complex of claim 1 , wherein the binding material is linked to cotinine via a PEG linker or an amino C6 linker.5. The complex of claim 1 , wherein the conjugate is bound to an antigen binding site of the anti-cotinine antibody.6. The complex of claim 1 , wherein the anti-cotinine antibody is selected from the group consisting of the antibody; an antibody fragment selected from Fab claim 1 , ScFv and domain antibodies; and a fusion protein comprising the antibody or the antibody fragment as a component.7. An in vitro biological assay method claim 1 , characterized by using a conjugate of cotinine and a binding material as an analysis tool.8. The method of claim 7 , wherein the in vitro biological assay method is selected from the group consisting of a flow cytometry claim 7 , a western blot analysis claim 7 , an immunoprecipitation assay claim 7 , and an enzyme-linked immunochemical assay.9. A method ...

Beverage Products

This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption.

Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder

A bioactive dose for delivering a bioactive agent to a mammal, includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit, the rapid release coating containing a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards an ideal absorptive pH or towards an ideal pH to hinder absorption of the at least one bioactive agent given the pKa that least at one bioactive agent. A modified liquid that is administered prior to, contemporaneous with, or following the delivery of a bioactive agent is also described. The liquid includes a pH modifier selected to control the pH of the liquid to a predetermined range so that the modified liquid rapidly modulates the pH of bodily fluids to enhance or hinder absorption of the bioactive agent.

COCRYSTALS OF P-COUMARIC ACID

Disclosed herein are cocrystals of p-coumaric acid and nicotinamide. A 1:1 molar ratio and a 2:1 molar ratio of p-coumaric acid to nicotinamide are herein disclosed. 1. A cocrystal of p-coumaric acid and nicotinamide.2. The cocrystal of wherein the molar ratio of p-coumaric acid to nicotinamide is 1:1.3. The cocrystal of having an x-ray powder diffraction pattern wherein there is at least one peak selected from 5.9 claim 2 , 11.8 claim 2 , 15.7 claim 2 , 17.1 claim 2 , 18.2 claim 2 , 18.9 claim 2 , 23.8 claim 2 , 25.0 claim 2 , 26.7 claim 2 , and 28.4 °2θ.4. The cocrystal of or having a DSC thermogram with an endotherm at about 155° C.5. The cocrystal of or having a C solid-state NMR spectrum wherein there is at least one peak selected from about 172.1 claim 2 , 160.8 claim 2 , 149.5 claim 2 , 147.6 claim 2 , 137.7 claim 2 , 132.5 claim 2 , 129.9 claim 2 , 128.9 claim 2 , 124.6 claim 2 , 120.6 claim 2 , 115.5 claim 2 , and 113.9 ppm.6. The cocrystal of wherein the XRPD pattern has a peak at about 5.9 °2θ claim 3 , a DSC endotherm at about 155° C. claim 3 , and a C solid-state NMR spectrum having a peak at about 172.1 ppm.7. The cocrystal of wherein the molar ratio of p-coumaric acid to nicotinamide is 2:1.8. The cocrystal of having an x-ray powder diffraction pattern wherein there is at least one peak selected from about 16.5 claim 7 , 17.6 claim 7 , 19.0 claim 7 , 22.5 claim 7 , 23.0 claim 7 , 23.8 claim 7 , 24.8 claim 7 , 27.1 claim 7 , and 27.3 °2θ.9. The cocrystal of or having a DSC thermogram with an endotherm at about 174.1° C.10. The cocrystal of or having a C solid-state NMR spectrum wherein there is at least one peak selected from about 175.4 claim 7 , 172.8 claim 7 , 169.8 claim 7 , 158.9 claim 7 , 150.0 claim 7 , 148.3 claim 7 , 145.2 claim 7 , 138.4 claim 7 , 135.0 claim 7 , 128.1 claim 7 , 126.4 claim 7 , 124.5 claim 7 , 116.9 claim 7 , 115.7 claim 7 , or 110.5 ppm.11. The cocrystal of wherein the XRPD pattern has a peak at about 17.6 °2θ claim 7 , a ...

PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and/or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and/or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like. 1. A composition comprisinga nicotine-containing material; andan agent comprising at least one of an anti-cancer agent, an anti-inflammatory agent, or a combination thereof.2. The composition according to claim 1 , wherein the agent comprises a phospho-NSAID.5. The composition according to claim 1 , wherein the agent comprises an anti-cancer agent and an anti-inflammatory agent.6. The composition according to claim 1 , wherein the agent comprises at least two anti-cancer agents.7. The composition according to claim 1 , wherein the agent comprises at least two anti-inflammatory agents.8. The composition according to claim 5 , wherein the agent comprises phospho-NSAID and curcumin.9. The composition according to claim 1 , wherein the nicotine-containing material is tobacco leaf.10. The composition according to claim 1 , wherein the composition contains nicotine and the agent in the ratio of from 1000:1 to 1:10 (wt:wt).11. The composition according to claim 1 , wherein the composition is provided in the form of a smoking device selected from the group consisting of cigarette claim 1 , cigar and smoking pipe.12. The composition according to claim 11 , wherein the smoking device includes a unit which ...

FORMULATION FOR TREATMENT OF DRY MOUTH AND MOUTH SORES

Serum compositions for application to endothelial tissue are described which contain an amniotic fluid extract in combination with embryonic stem cells. Formulations containing the serum composition are also described. The serum compositions and formulations may be used to treat conditions of the mouth such as dry mouth and mouth sores. 1. A serum composition comprising amniotic fluid and homogenized embryo mixed at a ratio of 70-100% amniotic fluid with 0-30% homogenized embryo , obtained from a chicken egg incubated for a period of 5-14 days after fertilization.2. The composition of claim 1 , wherein the incubation period is 7-8 days.3centella asiatica,. A formulation comprising the serum composition of claim 1 , aloe vera claim 1 , calendula extract claim 1 , and St. John's wort extract.4. The formulation according to further comprising at least two additional ingredients selected from the group consisting of hyaluronic acid claim 3 , DL-panthenol claim 3 , vegetable glycerin claim 3 , gluconodeltaloactone claim 3 , sodium benzoate claim 3 , licorice root extract claim 3 , niacinamide claim 3 , green tea extract claim 3 , olive leaf extract claim 3 , leucidal liquid claim 3 , goji berry extract claim 3 , salts claim 3 , and vitamin E.5. The formulation according to claim 4 , wherein the salts are selected from the group consisting of NaCl claim 4 , KCl claim 4 , NaHPO claim 4 , and KHPO.6. A method of treating dry mouth comprising administering the formulation of to a subject in need thereof.7. The method of claim 6 , wherein the formulation is administered as a spray into the mouth.8. The method of claim 7 , wherein the spray or pump is administered as needed.9. A method of treating a mouth sore claim 3 , comprising administering the formulation of to a subject in need thereof.10. The method of claim 9 , wherein the mouth sore is on the lips claim 9 , cheek claim 9 , tongue claim 9 , gums claim 9 , hard palate claim 9 , soft palate claim 9 , mouth floor claim 9 ...

CHEWING GUM HAVING SUSTAINED RELEASE OF NICOTINE

The present invention relates to a chewing gum having a high Surface Area to Volume ratio (SAV ratio), wherein said chewing gum comprises a water insoluble gum base matrix, a water soluble bulk portion and nicotine, wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1-10% of C8-C10 triglycerides by weight of the chewing gum. 113-. (canceled)14. Chewing gum having a high Surface Area to Volume ratio (SAV ratio) , wherein said chewing gum comprises:a water insoluble gum base matrix,a water soluble bulk portion and nicotine,wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1-10% of C8-C10 triglycerides by weight of the chewing gum, whereby less than 40% of the total nicotine content in the chewing gum is released from the chewing gum within the first 5 minutes from initiation of a chewing process carried out in vitro on a chewing machine in accordance with European Pharmacopeia 4th. ed. 2.9.25, with a phosphate buffer with a pH of 7.4.15. Chewing gum according to claim 14 , wherein the gum base comprises: elastomer in the range of 5-40% by weight of the gum base; natural resin in the range of 8-45% by weight of the gum base; and synthetic resin in the range of 5-50% by weight of the gum base.16. Chewing gum according to claim 14 , wherein the C8-C10 triglycerides have a degree of saturation of at least 80%.17. Chewing gum according to claim 14 , wherein the chewing gum comprises glycerin in an amount of between 0.001 and 2% by weight of the chewing gum.18. Chewing gum according to claim 14 , wherein the chewing gum comprises nicotine in an amount of 0.5-8 mg.19. Chewing gum according to claim 14 , wherein the nicotine is ...

COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO FALL AND FALL FREQUENCY IN NEURODEGENERATIVE DISEASES

The present disclosure provides methods and compositions for treating fall-related symptoms in patients with neurodegenerative diseases such as Parkinson's disease or Parkinson-related diseases. In some embodiments, the disclosure utilizes nicotine or a salt thereof in combination of dopaminergic agent treatments for reducing fall-related symptoms such as reducing frequency of fall, reducing injuries related to fall, reducing severity of injuries related to fall, freezing of gait, improving posture stability, improving locomotion ability, improving balance and gait. In some embodiments, the methods predict fall frequency and tendency of recurrent falls in patients with Parkinson's disease, in particular, patients with typical Parkinson's disease. 177-. (canceled)78. A method of administering nicotine or a salt thereof to a subject in need thereof , comprising:(a) administering a starting dose of the nicotine or salt thereof one time to six times a day for about 1 week to about 4 weeks, wherein the starting dose is about 1 mg;(b) administering a first escalating dose of the nicotine or salt thereof one time to six times a day for about 1 week to about 4 weeks, wherein the first escalating dose of the nicotine or salt thereof is about 2 mg;(c) optionally, administering a second escalating dose of the nicotine or salt thereof one time to six times a day for about 1 week to about 4 weeks, wherein the second escalating dose of the nicotine or salt thereof is about 4 mg;(d) optionally, administering a third escalating dose of the nicotine or salt thereof one time to four times a day for about 1 week to about 4 weeks, wherein the third escalating dose of the nicotine or salt thereof is about 6 mg; and 'wherein a total dose for administration is no more than 24 mg per day.', '(e) evaluating one or more parameters;'}79. The method of claim 78 , wherein the one or more parameters is an adverse event.80. The method of claim 78 , wherein the subject is evaluated for the one or ...

COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO FALL AND FALL FREQUENCY IN NEURODEGENERATIVE DISEASES

The present disclosure provides methods and compositions for treating fall-related symptoms in patients with neurodegenerative diseases such as Parkinson's disease or Parkinson-related diseases. In some embodiments, the disclosure utilizes nicotine or a salt thereof in combination of dopaminergic agent treatments for reducing fall-related symptoms such as reducing frequency of fall, reducing injuries related to fall, reducing severity of injuries related to fall, freezing of gait, improving posture stability, improving locomotion ability, improving balance and gait. In some embodiments, the methods predict fall frequency and tendency of recurrent falls in patients with Parkinson's disease, in particular, patients with typical Parkinson's disease. 161.-. (canceled)62. A kit comprising:(a) one or more starting unit doses of nicotine or a salt thereof for administration one time to six times a day for about 1 week to about 4 weeks, wherein no more than 1 mg of the nicotine or salt thereof is administered at each administration;(b) one or more first escalating unit doses of the nicotine or salt thereof for administration one time to six times a day for about 1 week to about 4 weeks, wherein no more than 2 times the one or more starting unit doses of the nicotine or salt thereof is administered at each administration;(c) optionally, one or more second escalating unit doses of the nicotine or salt thereof for administration one time to six times a day for about 1 week to about 4 weeks, wherein no more than 4 times the one or more starting unit doses of the nicotine or salt thereof is administered at each administration;(d) optionally, one or more third escalating unit doses of the nicotine or salt thereof for administration one time to four times a day for about 1 week to about 4 weeks, wherein no more than 6 times the one or more starting unit doses of the nicotine or salt thereof is administered at each administration; and(e) instructions for dose escalation of the ...

Oral dosage form containing theobromine-free cocoa

Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

SYSTEM AND METHOD FOR BIPHASIC TRANSDERMAL IONTOPHORETIC DELIVERY OF THERAPEUTIC AGENTS FOR THE CONTROL OF ADDICTIVE CRAVINGS

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., nicotine compounds for the treatment of nicotine cravings from tobacco use. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. 1. A system for transdermal iontophoretic delivery of a therapeutic agent to reduce an addictive craving in a patient , the system comprising an electrode assembly and a controller , the system configured to:position at least one electrode assembly in electrical communication with a skin of the patient, the at least one electrode assembly including a skin contacting layer and a solution comprising the therapeutic agent, wherein the therapeutic agent passively diffuses into the skin of the patient without application of an external force;deliver a dose of the therapeutic agent from the at least one electrode assembly into the skin of the patient during a first period using a first current having a polarity and magnitude to repel the therapeutic agent out of the electrode assembly, wherein delivering a dose of therapeutic agent includes a therapeutic agent delivery profile during the first period configured to mimic a delivery profile from the addictive craving;retain the therapeutic agent in the at least one electrode assembly during a second period using a ...

NICOTINE PARTICLE CAPSULE

A capsule containing particles including nicotine wherein a single aperture extends through the capsule. 1. A capsule containing particles comprising nicotine and defining an internal volume , wherein only a single aperture having a diameter from about 0.5 mm to about 1.5 mm extends through the capsule and is sized to provide a fraction amount of particles comprising nicotine and having a mass median aerodynamic diameter form about 0.5 micrometers to about 4 micrometers , at conventional smoking regime air flow rates of less than about 5 L/min once a piercing element used to form the single aperture is withdrawn from the single aperture.2. (canceled)3. (canceled)4. The capsule according to wherein the particles comprising nicotine have a mass median aerodynamic diameter and the single aperture has a diameter and wherein the ratio of the diameter of the single aperture to the mass median aerodynamic diameter of the particles comprising nicotine is from about 200 to about 800.5. The capsule according to claim 1 , wherein the nicotine comprises nicotine salt or nicotine salt hydrate.6. The capsule according to claim 1 , wherein the particles comprising nicotine comprise an amino acid.7. The capsule according to claim 1 , wherein the capsule contains particles comprising flavour and having a mean diameter of about 20 micrometres or greater claim 1 , or in a range from about 50 micrometres to about 150 micrometres.8. The capsule according to claim 1 , wherein the single aperture has an open surface area of from about 0.2 mmto about 1 mm.9. The capsule according to claim 1 , wherein the internal volume of the capsule is from about 0.2 ml to about 0.45 ml.10. The capsule according to claim 1 , wherein the single aperture has an open surface area in a range from about 0.7 mmto about 7 mmper ml of internal volume of the capsule.11. The capsule according to claim 1 , wherein the capsule contains from about 10 mg to about 200 mg of dry powder.12. The capsule according to claim ...

STABILIZED CANNABINOID COMPOSITIONS AND METHODS OF PREPARATION THEREOF

This disclosure provides cannabinoid compositions with improved shelf-life stability, methods of use thereof, and methods of preparation thereof. 1. A composition comprising one or more solubilized cannabinoids and at least one antioxidant , a metal chelator or a combination thereof.2. The composition of claim 1 , wherein the composition is formulated as an emulsion comprising a lipid phase and an aqueous phase claim 1 , the lipid phase comprising at least a fraction of the one or more cannabinoids and the aqueous phase comprising a first antioxidant.3. The composition of claim 2 , wherein the one or more cannabinoids comprise THC.4. The composition of claim 3 , wherein the THC is in an amount of between about 1 ppm and about 70 claim 3 ,000 ppm.5. The composition of claim 2 , wherein the first antioxidant comprises ascorbic acid.6. The composition of claim 5 , wherein the ascorbic acid is in an amount of between about 0.5 mM and about 1 mM of the aqueous phase.7. The composition of claim 2 , wherein the aqueous phase further comprises EDTA.8. The composition of claim 7 , wherein the EDTA is in an amount of between about 1 ppm and about 150 ppm.9. The composition of claim 2 , wherein the lipid phase comprises a second antioxidant.10. The composition of claim 9 , wherein the second antioxidant comprises tocopherol.11. The composition of claim 10 , wherein the tocopherol is in an amount of between about 2% and about 5% by weight of the lipid phase.12. The composition of claim 10 , wherein the composition comprises:between about 0.5 mM and about 1 mM of the ascorbic acid;between about 1 ppm and about 150 ppm of the EDTA; andbetween about 2% and about 5% by weight of the tocopherol.13. The composition of claim 2 , wherein the emulsion comprises emulsion droplets having a mean diameter of between about 50 nm and about 800 nm.14. The composition of claim 1 , wherein the one or more cannabinoids are solubilized through cyclodextrin-mediated encapsulation claim 1 , THC- ...

THERAPEUTIC COMPOSITION AND CONFIGURATION

A system intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The system preferably comprises a lozenge incorporating the active ingredient, adapted to provide oral administration of nicotine. The lozenge is in contact with a substrate (e.g., hollow tube) that can be manipulated within the mouth of the user (e.g., the hollow tube can be drawn upon to simulate the inhalation of cigarette smoke). As such, the active ingredient is administered and the user is able to experience certain other physiological sensations. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy. 1. A system for the administration of a therapeutic composition , the system comprising:a substrate portion having an upstream end and a downstream end, the upstream end allowing for passage of drawn atmospheric air into the substrate and the downstream end adapted for positioning into a user's mouth for draw upon the substrate and inhalation of atmospheric air by the user,a lozenge portion incorporating a source of active ingredient in a pharmaceutically acceptable form, the lozenge portion providing for oral ingestion of the active ingredient,the lozenge portion and the substrate portion being physically separate from one another but in contact with each other, the lozenge being positioned at the downstream end of the substrate, andthe lozenge and substrate portions being positioned so that the lozenge portion and a portion of the substrate portion can be located in the user's mouth during use, to provide for delivery of active ingredient from the lozenge and drawn air through the substrate.2. The system of claim 1 , wherein the active ingredient is a ...

THERAPEUTIC USES OF NICOTINE

The use of nicotine for treating inflammatory pain and hyphema is described. It is believed that inflammatory pain, such as renal pain, and hyphema can be improved by The various diseases, disorders or conditions can be improved by increasing the activity of α-melanocyte stimulating hormone (α-MSH), whose release is affected by nicotine. 1. A method of treating hyphema in a human subject in need thereof , comprising sublingually administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and an effective amount of nicotine.2. The method of claim 1 , wherein the composition is an aqueous pharmaceutical composition.3. The method of claim 1 , further comprising administering to the human subject one or more agents selected from the group consisting of an analgesic and an antibiotic.4. The method of claim 1 , wherein the pharmaceutical composition is an aqueous pharmaceutical composition consisting of water and an effective amount of nicotine.5. The method of claim 1 , wherein the pharmaceutical composition comprises 3 mg/ml nicotine.6. The method of claim 1 , wherein the composition is administered to the human subject at least once per day for a duration of at least 4 weeks.7. A method of treating an inflammatory pain in a human subject in need thereof claim 1 , comprising sublingually administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and an effective amount of nicotine.8. The method of claim 7 , wherein the inflammatory pain is renal pain.9. The method of claim 7 , wherein the composition is an aqueous pharmaceutical composition.10. The method of claim 7 , further comprising administering to the human subject one or more agents selected from the group consisting of an analgesic and an antibiotic.11. The method of claim 7 , wherein the pharmaceutical composition is an aqueous pharmaceutical composition consisting of water and an effective amount of ...

MODIFYING TASTE AND SENSORY IRRITATION OF SMOKELESS TOBACCO AND NON-TOBACCO PRODUCTS

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and/or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and/or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient. 1. A tobacco product comprising:a smokeless tobacco product having an individual product friability of at least 0.5 weight percent and less than 10 weight percent, a three point bend strength of at least 0.25 N and less than 4.0 N, and a texture profile hardness of at least 2.0 N and less than 12.0 N; andat least one active ingredient including castor oil, a major component thereof, or a derivative thereof as a taste receptor blocker.2. The tobacco product of claim 1 , wherein the smokeless tobacco product includes a pouch defining a plurality of pores.3. The tobacco product of claim 1 , wherein the smokeless tobacco product includes between 0.5 and 1.5 weight percent of a binder.4. The tobacco product of claim 3 , wherein the smokeless tobacco product includes between 0.6 and 0.8 weight percent of the binder.5. The tobacco product of claim 3 , wherein the binder includes guar gum claim 3 , xanthan claim 3 , cellulose claim 3 , or combinations thereof.6. The tobacco product of claim 1 , wherein the at least one active ingredient is an antagonist of nicotinic acetylcholine receptors (nAChRs) claim 1 , transient receptor potential (TRP) channels claim 1 , or a combination thereof.7. The tobacco product of claim 6 , wherein the transient receptor potential (TRP) channels include a TRPV1 channel claim 6 , a TRPA1 channel claim 6 , or a combination thereof.8. The ...

Composition and method for treating nucleic acid-related eye disease

Provided herein is a composition and a method for treating nucleic acid-related eye disease.

DRUG DOSE CARTRIDGE FOR AN INHALER DEVICE

Devices and methods are described for preparing, managing, and/or administering metered doses of substances for vaporized administration. In some embodiments, dose cartridges comprising at least one botanical substance include a heating element integrated into the cartridge in close contact with the botanical substance. In some embodiments, cartridge-mounted doses are stored in a magazine, optionally in carousel form, before use. Transport of a cartridge from a magazine to an electrically operated vaporizing chamber which activates the heating element is provided by a mechanical pickup means. 1. A dose cartridge container comprising a plurality of dose cartridges within a closed container to be used in an inhaler device , wherein the dose cartridge container is a carousel dose cartridge container such that the carousel provides selectable access to dose cartridges positions in the carousel.2. The dose cartridge container of claim 1 , wherein the carousel provides selectable access by being revolved within a carousel enclosure.3. The dose cartridge container of claim 1 , wherein the carousel is configured to allow access to dose cartridges in the sequential order of the dose cartridges positions within the carousel.4. The dose cartridge container of claim 1 , wherein the carousel is configured to allow access to dose cartridges in an order different from the sequential order of the dose cartridges positions within the carousel.5. The dose cartridge container of claim 1 , wherein the carousel is configured to allow access to dose cartridges according to their specified location in the dose cartridge container.6. The dose cartridge container of claim 1 , wherein the number of the dose cartridges carried by the dose cartridge container is within the range of 10-200 doses.7. The dose cartridge container of claim 1 , wherein each of the plurality of dose cartridges comprises a drug substance.8. The dose cartridge container of claim 1 , wherein the plurality of dose ...

PRODUCT PACKAGING WITH HEAT SEALABLE BARRIER MATERIAL

A package that is suitable for packaging an article for collecting or administering a pharmaceutical active substance is disclosed. The package includes a first packaging component that includes a product-contacting sealant layer that includes a first ethylene vinyl alcohol copolymer. The package includes a second packaging component that includes a product-contacting sealant layer that includes a second ethylene vinyl alcohol copolymer. The ethylene content of the second ethylene vinyl alcohol copolymer is equal to or less than about 38 percent and the ethylene content of the first ethylene vinyl alcohol copolymer is greater than the ethylene content of the second ethylene vinyl alcohol copolymer. 1. A package comprising:a first packaging component comprising a product-contacting sealant layer comprising a first ethylene vinyl alcohol copolymer; anda second packaging component comprising a product-contacting sealant layer comprising a second ethylene vinyl alcohol copolymer;wherein the ethylene content of the second ethylene vinyl alcohol copolymer is equal to or less than 38 percent, and wherein the ethylene content of the first ethylene vinyl alcohol copolymer is greater than the ethylene content of the second ethylene vinyl alcohol copolymer.2. A package according to claim 1 , wherein the ethylene content of the second ethylene vinyl alcohol copolymer is 38 percent.3. A package according to claim 2 , wherein the ethylene content of the first ethylene vinyl alcohol copolymer is greater than 38 percent.4. A package according to claim 1 , wherein the first packaging component comprises at least 95 wt. percent of the first ethylene vinyl alcohol copolymer and the second packaging component comprises at least 95 wt. percent of the second ethylene vinyl alcohol copolymer.5. A package according to claim 1 , wherein the first packaging component consists essentially of the first ethylene vinyl alcohol copolymer and the second packaging component consists essentially of ...

TOBACCO- AND SMOKE-LESS PRODUCTS CONSUMABLE BY HUMANS AS EPICUREAN OR MEDICAL PRODUCTS AND METHOD OF TREATING SMOKING ADDICTION

A tobacco and smoke-less product comprises a first quantity of a first compound in a form suitable to release in-vivo in a human body a dose of a nicotinic agonist tolerable by the human body and sufficient to provide a sensation similar to that of nicotine released into the body by smoking tobacco. The product further comprises a second quantity of a second compound in a form suitable to release in-vivo in the human body a dose of non-psychoactive cannabinoid tolerable by the human body which reduces the desire to smoke tobacco. The product can be e.g. an epicurean product or a medical product, e.g. to treat smoking addition. The product can be provided in a kit of two or more products, such as to release different doses of the nicotinic agonist. 1. A tobacco- and smokeless product , comprising:a first quantity of a first compound in a form suitable to release in-vivo in a human body a dose of a nicotinic agonist, which dose is tolerable by the human body and sufficient to provide a sensation similar to that of nicotine released into the body by smoking tobacco; anda second quantity of a second compound in a form suitable to release in-vivo in the human body a dose of non-psychoactive cannabinoid, which dose is tolerable by the human body and reduces the desire to smoke tobacco.2. Product according to claim 1 , wherein the non-psychoactive cannabinoid has a metabolic pathway in the human body different from a metabolic pathway of tetrahydrocannabinol.3. Product according to claim 1 , wherein the non-psychoactive cannabinoid acts on a metabolic pathway of endogenous cannabinoid ligands.4. Product according to claim 1 , wherein the non-psychoactive cannabinoid is an antagonist to CB1 and/or CB2 receptors in the human body.5. Product according to claim 4 , wherein the non-psychoactive cannabinoid is an indirect antagonist of exogeneous CB1 and/or CB2 agonists.6. Product according to claim 3 , wherein the non-psychoactive cannabinoid increases a concentration of ...

Alprostadil and lidocaine treatment of premature ejaculation

Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C 1 to C 8 alcohol, an aliphatic C 8 to C 30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical. 1. A pouched product adapted for oral use , comprising:a water-permeable fabric pouch formed so as to define a cavity therein;a composition contained within the cavity of the water-permeable fabric pouch, the composition comprising one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch, the composition comprising nicotine and at least one particulate non-tobacco material; andat least one capsule contained within the cavity of the water-permeable fabric pouch, the at least one capsule having a capsule wall surrounding an inner payload comprising at least one botanical.2. The pouched product of claim 1 , wherein the capsule wall comprises a material configured to be broken by shear forces.3. The pouched product of claim 1 , wherein the at least one particulate non-tobacco material comprises microcrystalline cellulose.4. The pouched product of claim 1 , wherein the nicotine is synthetic nicotine.5. The pouched product of claim 4 , wherein the synthetic nicotine is in the form of S(−)-nicotine or a racemic mixture composed predominantly of S(−)-nicotine.6. The pouched product of claim 1 , ...

DILUENTS FOR COMPOSITIONS OF CANNABINOIDS AND USES THEREOF

The present invention provides a stock compositions comprising a combinations of terpenes, that, when used as diluents in vaporizable formulations comprising cannabinoids, confer administration of reproducible constant dose of the formulations and its components such as cannabinoids, reduce throat irritation and improve the flavor of said formulations. The invention further provides vaporizable formulations comprising defined concentrations of the diluent(s) and cannabinoids. Use of the vaporizable formulations is provided as well. 1. A vaporizable formulation comprising (i) a cannabinoid , (ii) from 0.5 to 10 wt % of nicotine , and (iii) at least one diluent , wherein the cannabinoid is selected from CBD , CBDA or a combination thereof.2. The vaporizable formulation according to claim 1 , wherein the least one diluent has a boiling point of at least 140° C. claim 1 , at least 200° C. claim 1 , at least 290° C. or at least 350° C.3. The vaporizable formulation according to claim 1 , wherein the least one diluent is selected from the group consisting of natural bisabolol claim 1 , sesquiterpenes claim 1 , diterpenes claim 1 , medium chain triglycerides (MCT) claim 1 , glyceryl trioctanoate claim 1 , glyceryl tridecanoate claim 1 , squalane claim 1 , triethyl citrate claim 1 , PEG and any combination thereof.4. The vaporizable formulation according to claim 1 , comprising from 50 to 90 wt % of the diluent.5. The vaporizable formulation according to claim 4 , wherein the diluent is (C8-C12) medium chain triglycerides.6. The vaporizable formulation according to claim 5 , wherein the diluent is glyceryl trioctanoate.7. The vaporizable formulation according to claim 4 , comprising from 5 to 25 wt % of the cannabinoid.8. The vaporizable formulation according to claim 1 , comprising from 5 to 50 wt % of the diluent.9. The vaporizable formulation according to claim 1 , comprising from 5 to 20 wt % of the diluent.10. The vaporizable formulation according to claim 8 , wherein ...

DRUG DOSE CARTRIDGE FOR AN INHALER DEVICE

Devices and methods are described for preparing, managing, and/or administering metered doses of substances for vaporized administration. In some embodiments, dose cartridges comprising at least one botanical substance include a heating element integrated into the cartridge in close contact with the botanical substance. In some embodiments, cartridge-mounted doses are stored in a magazine, optionally in carousel form, before use. Transport of a cartridge from a magazine to an electrically operated vaporizing chamber which activates the heating element is provided by a mechanical pickup means. 1. A dose cartridge dispensing assembly comprising:a dose cartridge dispenser which stores a plurality of dose cartridges therein; the dose cartridge dispenser comprising a housing including at least one aperture leading into and out of an inner volume defined by said housing;at least one administration element shaped and sized to be at least partially inserted into said at least one aperture, said administration element configured to carry a dose cartridge out from said dose cartridge dispenser or back into said dose cartridge dispenser via said at least one aperture; wherein said administration element is configured to engage a first dose cartridge in a manner which geometrically blocks engagement of said administration element to another, second dose cartridge, such that removal of said second dose cartridge from said dose cartridge dispenser is enabled only when said first dose cartridge is returned by said administration element back into said dose cartridge dispenser.2. The assembly according to claim 1 , wherein said plurality of dose cartridges are arranged on a carousel inside said housing of said dose cartridge dispenser claim 1 , and wherein insertion of said administration element into said at least one aperture triggers rotation of said carousel.3. The assembly according to claim 1 , wherein said plurality of dose cartridges are transported within said housing ...

COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS

The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration. 1. An oral pulsatile release dosage form for once-daily oral administration , said form comprising an effective amount of nicotine or a salt thereof for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease or for delay in progression of Parkinson's Disease , wherein said form exhibits first , second , third , and fourth pulsatile releases of nicotine or salt thereof;wherein said first pulsatile release occurs with a maximum release within two hours of administration, said second pulsatile release occurs with a maximum release between five and seven hours following administration, said third pulsatile release occurs with a maximum release between eleven and thirteen hours following administration, and said fourth pulsatile release occurs with a maximum release between sixteen and twenty hours following administration; or wherein said first pulsatile release occurs with a maximum release between about two to four hours of administration, said second pulsatile release occurs with a maximum release between seven and nine hours following administration, said third pulsatile release occurs with a maximum release between thirteen and fifteen hours following administration, and said fourth pulsatile release occurs with a maximum release between eighteen and twenty-two hours following administration; orwherein said first pulsatile release occurs with a maximum release within two hours of entering the small intestine, said second pulsatile release occurs with a ...

NANO- MICRODELIVERY SYSTEMS FOR OROMUCOSAL DELIVERY OF AN ACTIVE INGREDIENT

A composition for oromucosal delivery of at least one active ingredient, more particularly a lipid nano-microdelivery system comprising a nicotine component and/or a flavour component, wherein the nicotine component may be delivered to the oral cavity via absorption through the mucosal membranes thereof and/or wherein the flavour component may be delivered to the oral mucosa by controlled release. 1. A composition for oromucosal delivery of at least one active ingredient comprising:a lipid nano-micro-structure comprising at least one lipid and at least one active ingredient selected from the group consisting of a nicotine component and a flavour component, said at least one active ingredient being immobilised in said lipid nano-micro-structure.2. The composition according to claim 1 , wherein said lipid nano-micro-structure is selected from the group comprising lipid nano-microparticles claim 1 , lipid nano-microfibres claim 1 , nano-microparticles encapsulated/immobilised in lipid nano-microfibres claim 1 , lipid nano-microparticles encapsulated/immobilised in polymer nano-microfibers claim 1 , lipid nano-microparticles encapsulated/immobilised in polymer nano-microparticles claim 1 , nano-micro structured lipid carriers (N-MLC's) claim 1 , lipid drug conjugate (LDC) nano-microparticles claim 1 , and polymer-lipid hybrid nano-microparticles (PLNM) claim 1 , and any combinations thereof.3. The composition according to claim 1 , wherein said nicotine component is selected from the group consisting of nicotine base and a salt of nicotine.4. The composition according to claim 1 , wherein said flavour component is selected from the group consisting of one or more components of vanilla claim 1 , one or more components of spearmint claim 1 , one or more components of orange claim 1 , menthol claim 1 , one or more components of nutmeg claim 1 , of one or more components of eucalyptus claim 1 , one or more components of cinnamon claim 1 , one or more components of thyme ...

Methods for Treating Acne Vulgaris

Methods for treating acne vulgaris include providing a solution having a peroxide compound, the solution having an antimicrobial effect for reducing bacteria that cause acne vulgaris; topically administering a therapeutically effective amount of the solution to the patient; and once administered, exposing the solution to a wavelength of light that creates a synergistic antimicrobial effect with the solution and enhances the antimicrobial effect of the solution, thereby further reducing or eliminating the bacteria that cause acne vulgaris. The methods may decrease lesions and associated inflammation in patients infected with acne vulgaris,

Vaginal Drug Delivery Device

The present invention relates to a vaginal drug delivery device configured for placement within the vagina, comprising a housing, at least one reservoir comprising a biologically active compound that is not normally administered via the vagina and means for the controlled release of the compound from the reservoir into the vagina. Suitably the vaginal device further comprising means for gathering physiological data of a person carrying the device in her vagina. Alternatively, the vaginal drug delivery device configured for placement within the vagina, comprises a housing and means for gathering physiological data of a person carrying the device in her vagina. The invention further relates to oxybutynin for use in the treatment of urinary and bladder problems, in particular urge incontinence, wherein oxybutynin is administered to a person in need of treatment by means of the vaginal device, and to other therapeutic compounds that are administered via the vaginal device for use in their corresponding indications. 1. A vaginal drug delivery device configured for placement within the vagina , comprising a housing , at least one reservoir comprising a biologically active compound that is not normally administered via the vagina and means for the controlled release of the compound from the reservoir into the vagina.2. The vaginal device as claimed in claim 1 , further comprising means for gathering physiological data of a person carrying the device in her vagina.3. The vaginal device as claimed in claim 1 , wherein the means for the controlled release of the compound from the reservoir are configured to act in response to physiological data of a person carrying the device in her vagina.4. The vaginal device as claimed in claim 1 , wherein the means for the controlled release of the compound from the reservoir are operated remotely claim 1 , in particular by the person carrying the device in her vagina claim 1 , a nurse or a physician.5. The vaginal device as claimed in ...

Neprilysin inhibitors

In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

NICOTINE GEL

A gel composition is provided, including an alkaloid compound, or a cannabinoid compound, or both an alkaloid compound and a cannabinoid compound; glycerol; a viscosifying agent; a hydrogen-bond crosslinking gelling agent; and an ionic crosslinking gelling agent. 116.-. (canceled)17. A gel composition , comprising:an alkaloid compound, or a cannabinoid compound, or both an alkaloid compound and a cannabinoid compound;at least about 50% wt. glycerol;at least about 0.2% wt. viscosifying agent;at least about 0.2% wt. hydrogen-bond crosslinking gelling agent; andat least about 0.2% wt. ionic crosslinking gelling agent.18. The gel composition according to claim 17 , wherein the alkaloid compound is nicotine.19. The gel composition according to claim 17 , wherein the composition comprises about 70% to about 80% wt. glycerol.20. The gel composition according to claim 17 , wherein the viscosifying agent claim 17 , the hydrogen-bond crosslinking gelling agent claim 17 , and the ionic crosslinking gelling agent are present in the gel composition in a total amount from about 1% wt. to about 8% wt.21. The gel composition according to claim 17 , wherein the viscosifying agent claim 17 , the hydrogen-bond crosslinking gelling agent claim 17 , and the ionic crosslinking gelling agent are each present in the gel composition in a range from about 0.5% wt. to about 2% wt.22. The gel composition according to claim 17 , further comprising water in a range from about 1% wt. to about 30% wt.23. The gel composition according to claim 17 , comprising:about 0.5% wt. to about 2.5% wt. nicotine;about 70% wt. to about 80% wt. glycerol;about 0.5% wt. to about 2% wt. viscosifying agent;about 0.5% wt. to about 2% wt. hydrogen-bond crosslinking gelling agent;about 0.5% wt. to about 2% wt. ionic crosslinking gelling agent;about 15% wt. to about 25% wt. water; anddivalent cations.24. The gel composition according to claim 17 , wherein the viscosifying agent comprises xanthan gum claim 17 , ...

NICOTINE SALT FORMULATIONS FOR AEROSOL DEVICES AND METHODS THEREOF

A nicotine salt liquid formulation for generating an inhalable aerosol in an electronic cigarette comprising nicotine salt that forms about 0.5% to about 20% nicotine is provided. 1. A method of delivering nicotine to a user comprising deploying an electronic cigarette comprising a nicotine formulation comprising nicotine in a biologically acceptable liquid carrier , wherein operation of the electronic cigarette generates an inhalable aerosol , and wherein inhalation of the aerosol at a rate of about one inhalation per 30 seconds results in a nicotine plasma Tfrom about 3 min to about 8 min.2. The method of claim 1 , wherein the nicotine plasma Tis from about 3 min to about 7 min claim 1 , from about 3 min to about 6 min claim 1 , from about 3 min to about 5 min claim 1 , from about 3 min to about 4 min claim 1 , from about 4 min to about 8 min claim 1 , from about 4 min to about 7 min claim 1 , from about 4 min to about 6 min claim 1 , from about 4 min to about 5 min claim 1 , from about 5 min to about 8 min claim 1 , from about 5 min to about 7 min claim 1 , from about 5 min to about 6 min claim 1 , from about 6 min to about 8 min claim 1 , from about 6 min to about 7 min claim 1 , from about 7 min to about 8 min claim 1 , less than about 8 min claim 1 , less than about 7 min claim 1 , less than about 6 min claim 1 , less than about 5 min claim 1 , less than about 4 min claim 1 , about 8 min claim 1 , about 7 min claim 1 , about 6 min claim 1 , about 5 min claim 1 , about 4 min claim 1 , or about 3 min.3. The method of claim 1 , wherein the Tis determined based on at least three independent data sets.4. The method of claim 1 , wherein the Tis a range of at least three independent data sets.5. The method of claim 1 , wherein the Tis an average±a standard deviation of at least three independent data sets.6. The method of claim 1 , wherein the nicotine formulation comprises a nicotine salt comprising nicotine and an acid.7. The method of claim 6 , wherein nicotine ...

Method for Treating a Pulmonary Disease State in Mammals by Up Regulating Indigenous in vivo Levels of Inflammatory Agents in Mammalian Cells

The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine. 1. A method for treating a disease state in mammals characterized by abnormally low levels of inflammatory agents by up-regulating indigenous in vivo levels of an inflammatory agent comprising:a. contacting the mammalian cells with an inflammatory regulator, comprising at least 2.8 mg pyruvate, or a pyruvate precursor or salt thereof, α-keto-isovaleric acid or a precursor thereof and mixtures thereofb. wherein said inflammatory agents are selected from the group consisting of elastase, white blood cells, tumor necrosis factor-α and cytokines selected from the group consisting of interleukin-6, interleukin-8, interleukin-10, interleukin-17, and interleukin-23, and;c. wherein the disease state is selected from the group consisting of pulmonary and upper respiratory diseases, Alzheimer's disease, diabetes, and nicotine addiction.2. The method of wherein the pulmonary and upper respiratory disease is selected from the group consisting of infected lungs and infected sinuses claim 1 , bronchial asthma claim 1 , acute bronchitis claim 1 , allergic rhinitis claim 1 , sinusitis and diseases caused by organic dust claim 1 , irritant gases claim 1 , air ...

MEDICAL CHEWING GUM

The invention relates to a medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient, the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and -80% by weight of vinyl laurate-vinyl acetate copolymer, and wherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin. 162-. (canceled)63. A medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient ,the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight,wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer, andwherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin.64. The medical chewing gum according to claim 63 , the medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient claim 63 ,the gum base polymers consisting of synthetic gum base polymers, andthe gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight,wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer, andwherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin.65. The medical chewing gum according to claim 63 , the medical chewing gum comprising gum base polymers claim 63 , an active pharmaceutical ingredient and buffer claim 63 ,the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight,wherein the gum base polymers include 20-95% by weight of ...

FOOD AND BEVERAGE COMPOSITIONS INFUSED WITH LIPOPHILIC ACTIVE AGENTS AND METHODS OF USE THEREOF

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents. 120-. (canceled)21. A lipophilic active agent infused food product comprising:(a) a therapeutically effective amount of a lipophilic active agent, wherein the lipophilic active agent is selected from the group consisting of a cannabinoid, nicotine, a non-steroidal anti-inflammatory drug (NSAID), and a vitamin;(b) a bioavailability enhancing agent, wherein the bioavailability enhancing agent enhances the bioavailability of the lipophilic active agent; and(c) a food product, wherein the food product is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.23. The lipophilic active agent infused food product of claim 22 , wherein the bioavailability enhancing agent is a protective colloid claim 22 , an edible oil or fat claim 22 , and a lipophilic active agent taste masking agent.24. The lipophilic active agent infused food product of claim 23 , wherein the bioavailability enhancing agent that is a protective colloid claim 23 , an edible oil or fat claim 23 , and a lipophilic active agent taste masking agent is nonfat dry milk.25. The lipophilic active agent infused food product of claim 24 , wherein the bioavailability enhancing agent is substantially free of omega-6 fatty acids.26. The lipophilic active agent infused food product of any one of claim 22 , wherein the bioavailability of the lipophilic active agent in a ...

POUCHED PRODUCT WITH LIQUID FLAVOR COMPOSITION

An oral pouched product is disclosed, the pouched product comprising a saliva permeable pouch and a pouch composition, the pouch composition comprising a powdered composition, water, and a liquid flavor composition, wherein the liquid flavor composition is added to the powdered composition after the water. A further oral pouched product and a method of manufacturing an oral pouched product is disclosed. 1. An oral pouched product comprising a saliva permeable pouch and a pouch composition , a powdered composition,', 'water, and', 'a liquid flavor composition,, 'the pouch composition comprising'}wherein the powdered composition comprises water-insoluble fiber,wherein the powdered composition comprises at least one sugar alcohol in an amount of 5-70% by weight of the pouch composition, andwherein the liquid flavor composition is added to the powdered composition after the water.2. The oral pouched product according to claim 1 , wherein the pouch composition further comprises a powdered flavor composition.3. The oral pouched product according to claim 1 , wherein the pouch composition comprises a powdered flavor composition in an amount of at least 1% by weight of the pouch composition.4. (canceled)5. The oral pouched product according to claim 1 , wherein the pouch composition comprises the liquid flavor composition in an amount of at least 0.01% by weight of the pouch composition.69.-. (canceled)10. The oral pouched product according to claim 3 , wherein the powdered flavor provides flavor compound in an amount of 0.1 to 18% by weight of the pouch composition.1112.-. (canceled)13. The oral pouched product according to claim 5 , wherein the liquid flavor composition provides flavor compound in an amount of 0.01 to 5% by weight of the pouch composition.1415.-. (canceled)16. The oral pouched product according to claim 1 , wherein the at least one sugar alcohol is selected from the group consisting of xylitol claim 1 , maltitol claim 1 , mannitol claim 1 , erythritol ...

NICOTINE SALT WITH META-SALICYLIC ACID AND APPLICATIONS THEREIN

The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation. 1. A drug supply article comprising:a heat-conductive substrate having an impermeable surface;a nicotine composition comprising nicotine meta-salicylate coated on at least a portion of the surface in the form of a film having a thickness; anda heat source operable to supply heat to the substrate at a rate that achieves a temperature sufficient to vaporize all or a portion of the coated nicotine composition within a period of 2 seconds;wherein the vaporized nicotine composition comprises an effective amount of the nicotine;wherein the film has a thickness between 0.05 and 30 microns.2. The drug supply article of claim 1 , wherein the nicotine composition comprises a pharmaceutically acceptable excipient.3. The drug supply article of claim 1 , wherein the film thickness is between 0.1 and 30 microns. This application is a continuation of U.S. application Ser. No. 14/904,359, filed Jan. 11, 2016, entitled “Nicotine Salt with Meta-Salicylic Acid and Applications Therein”, which application claims priority to PCT/US2014/046288, filed Jul. 11, 2014, entitled “Nicotine Salt with Meta-Salicylic Acid and Applications”, which application claims priority to U.S. provisional application Ser. No. 61/845,333 entitled “Nicotine Salt with Meta-Salicylic Acid,” filed Jul. 11, 2013, Myers and application claims priority to U.S. provisional application Ser. No. 62/020,766 entitled “Drug ...

INHIBITORS OF MICROBIALLY INDUCED AMYLOID

The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed. 1. A method of inhibiting , ameliorating , reducing the likelihood , delaying the onset of , or treating a microbially induced amyloid disorder , the method comprising administering to a subject in need thereof a composition comprising a compound selected from the group consisting of: epigallocatechin gallate , quercetin , morin , rosmarinic acid , gallic acid , lauryl gallate , methoxyhydroquinone , curcumin , resveratrol , apigenin , nordihydroguaiaretic acid , phloretin and genistein; or pharmaceutically acceptable salts thereof.2. The method of claim 1 , wherein the microbially induced amyloid disorder is α-synucleinopathy claim 1 , Parkinson's Disease claim 1 , Lewy Body Dementia claim 1 , incidental Lewy body disease claim 1 , Lewy body variant of Alzheimer's disease claim 1 , multiple system atrophy claim 1 , pure autonomic failure claim 1 , intestinal dysbiosis claim 1 , intestinal hyperpermeability claim 1 , irritable bowel syndrome (IBS) claim 1 , inflammatory bowel disease (IBD) claim 1 , ulcerative colitis claim 1 , or Crohn's disease or any combination thereof.3. The method of claim 1 , wherein the subject suffers from gastrointestinal symptoms comprising one or more of dysphagia claim 1 , reduced gut motility claim 1 , gastroparesis claim 1 , constipation claim 1 , small intestine bacterial overgrowth (SIBO) claim 1 , diarrhea claim 1 , abdominal pain and/or cramping claim 1 , bloating claim 1 , flatulence claim 1 , and nausea.4. The method of claim 3 , wherein the gastrointestinal symptoms are ...

ARTICLE AND METHODS FOR ORAL SELF-ADMINISTRATION OF NICOTINE

The invention discloses an article for swaddling in the mouth to deliver pharmacologically active substances, particularly nicotine, in combination with dyes or flavorings, across the buccal membranes when said article is swaddled in the mouth. The article comprises a non-edible substantially cylindrical core element, such as a toothpick, and the indicator element may be a bulb, trinket, insignia or other marking. In a preferred embodiment, the invention makes a social statement about the beneficial uses of nicotine. Methods for using the invention to mitigate sensations of nervousness and boredom are also disclosed. 1. An article to be swaddled in the mouth of a person for oral self-administration of nicotine , the article comprising:a core element comprising an absorbent material having an elongate shape, said core element having been soaked in a solution comprising a nicotine solution, wherein said nicotine solution comprises nicotine extract, vegetable glycerin, and distilled water;wherein said absorbent material of said core element is indigestible, such that while being swaddled in the mouth it retains said shape and is not digested by the digestive secretions of the human organism.2. The article of claim 1 , wherein the nicotine solution further comprises at least one of flavorants claim 1 , dyes claim 1 , organoleptic agents claim 1 , preservatives claim 1 , solvents claim 1 , and buffering agents.3. The article of claim 2 , wherein the buffering agent is an alkaline salt.4. The article of claim 1 , wherein the nicotine extract is present in the nicotine solution in a concentration of 0.5 to 10%.5. The article of claim 4 , wherein the vegetable glycerin is present in the nicotine solution in a concentration of 45 to 85%.6. The article of claim 5 , wherein distilled water is present in the nicotine solution in a concentration of 20 to 50%.7. The article of claim 6 , wherein the nicotine solution further comprises at least one of flavorants claim 6 , dyes ...

Health Supplement using Guarana Extract

The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethylaminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum tenuiflorum, one or more teas such as green tea, white tea or black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline (INN), Huperzine A, and Vinpocetine.

Compositions and methods for treatment in parkinson's disease patients

The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration.

PHOTOLABILE COMPOUNDS

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule. 2. The compound of claim 1 , wherein each Lis independently an organic molecule having a —CN group whose nitrogen atom forms a bond with Ru.3. The compound of claim 1 , wherein the organic molecule is methyl beta-D-1-thiogalactopyranoside.4. The compound of claim 1 , wherein the organic molecule is isopropyl beta-D-1-thiogalactopyranoside.5. The compound of claim 1 , wherein the organic molecule is mercaptopurine claim 1 , thioguanine claim 1 , doxorubicin claim 1 , cytarabin claim 1 , temozolomide or gentamicin.6. The compound of claim 1 , wherein the organic molecule is mercaptopurine.7. The compound of claim 1 , wherein the organic molecule is thioguanine.8. The compound of claim 1 , wherein the organic molecule is doxorubicin.9. The compound of claim 1 , wherein the organic molecule is cytarabin.10. The compound of claim 1 , wherein the organic molecule is temozolomide.11. The compound of claim 1 , wherein the organic molecule is gentamicin.12. The compound of or claim 1 , wherein the organic molecule is benzonitrile claim 1 , 3-butenenitrile or 2-cyanophenol.13. The compound of claim 1 , wherein the organic molecule is an amino acid or a protected amino acid.14. The compound of or claim 1 , wherein the organic molecule is methionine.15. The compound of or ...

FLAVOURED NICOTINE POWDER INHALER

This disclosure relates to flavoured nicotine powder inhalers where the nicotine powder is delivered at air flow rates that mimic a smoking regime. 1. A nicotine powder inhaler comprising:a body extending between a mouthpiece portion and a distal end portion;an airflow channel extending between the mouthpiece portion and a distal end portion;a nicotine powder receptacle disposed along the airflow channel and comprising a dose of nicotine powder and;a flavour delivery element in fluid connection with the airflow channel;wherein the dose of nicotine powder can be inhaled into lungs of a user at an inhalation rate of less than about 5 L/min.2. A nicotine powder inhaler according to claim 1 , wherein the flavour delivery element is upstream of the nicotine powder receptacle.3. A nicotine powder inhaler according to claim 1 , wherein the flavour delivery element is downstream of the nicotine powder receptacle.4. A nicotine powder inhaler according to claim 1 , further comprising a second airflow channel comprising a flavour receptacle wherein the flavour receptacle is in parallel flow relation with the nicotine powder receptacle.5. A nicotine powder inhaler according to claim 1 , wherein the flavour element comprises powdered flavourant.6. A nicotine powder inhaler according to claim 1 , wherein the flavour element comprises liquid flavourant.7. A nicotine powder inhaler according to claim 1 , wherein the nicotine powder receptacle is configured to receive a capsule containing nicotine powder comprising nicotine salt.8. A nicotine powder inhaler according to claim 7 , wherein the capsule further contains the flavour delivery element comprising powdered flavourant.9. A nicotine powder inhaler according to claim 1 , wherein the flavour delivery element comprises a crushable capsule that can be ruptured by a user to release flavourant.10. A nicotine powder inhaler according to claim 1 , further comprising a filter element upstream of the nicotine powder receptacle and the ...

FOOD AND BEVERAGE COMPOSITIONS INFUSED WITH LIPOPHILIC ACTIVE AGENTS AND METHODS OF USE THEREOF

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents. 2. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , wherein the bioavailability of the nicotine in a subject is at least 3 times greater than the bioavailability of the nicotine in the subject in the absence of the bioavailability enhancing agent.3. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , wherein the bioavailability of the nicotine in a subject is at least 4.5 times greater than the bioavailability of the nicotine in the subject in the absence of the bioavailability enhancing agent.4. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , wherein the bioavailability enhancing agent is free of omega-6 fatty acids.5. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , wherein the bioavailability enhancing agent is a protective colloid claim 1 , an edible oil or fat claim 1 , and a nicotine taste masking agent.6. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , wherein the bioavailability enhancing agent is nonfat dry milk.7. The nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder of claim 1 , further wherein the nicotine infused tea leaves claim 1 , coffee beans claim 1 , or cocoa powder are lyophilized.9. The nicotine infused beverage product of claim 8 , wherein the bioavailability of the nicotine in a ...

Food and beverage compositions infused with lipophilic active agents and methods of use thereof

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

LIQUID NICOTINE FORMULATION COMPRISING LOW MOLAR MASS METAL SALT

A liquid nicotine formulation for an aerosol-generating system is provided, the nicotine formulation including: one or more water-miscible polyhydric alcohols, the nicotine formulation having a water-miscible polyhydric alcohol content of greater than or equal to about 5 percent by weight; and one or more low molar mass metal salts, the one or more low molar mass metal salts being selected from the group consisting of metal cinnamates, metal cycloheptanecarboxylates, metal levulinates, metal propanoates, metal stearates, and metal undecanoates. An aerosol-generating article and an aerosol-generating system are also provided. 114.-. (canceled)15. A liquid nicotine formulation for an aerosol-generating system , the nicotine formulation comprising:one or more water-miscible polyhydric alcohols, wherein the nicotine formulation has a water-miscible polyhydric alcohol content of greater than or equal to about 5 percent by weight; andone or more low molar mass metal salts, wherein the one or more low molar mass metal salts are selected from the group consisting of metal cinnamates, metal cycloheptanecarboxylates, metal levulinates, metal propanoates, metal stearates, and metal undecanoates.16. The liquid nicotine formulation according to claim 15 , wherein the one or more low molar mass metal salts are one or more low molar mass non-saccharide metal salts.17. The liquid nicotine formulation according to claim 15 , wherein the one or more low molar mass metal salts are sodium stearate.18. The liquid nicotine formulation according to claim 15 , wherein the nicotine formulation has a low molar mass metal salt content of between about 0.5 percent and about 15 percent by weight.19. The liquid nicotine formulation according to claim 15 , wherein the nicotine formulation has a water-miscible polyhydric alcohol content of at least about 60 percent by weight.20. The liquid nicotine formulation according to claim 15 , wherein the one or more water-miscible polyhydric alcohols ...

LIQUID NICOTINE FORMULATION COMPRISING WATER-IMMISCIBLE SOLVENTS

A liquid nicotine formulation for an aerosol-generating system is provided, the liquid nicotine formulation including: at least one of water and one or more water-miscible solvents; one or more partially water-soluble, water-immiscible solvents having a water solubility at 20° C. of between about 20 mg/ml and about 100 mg/ml; and one or more water insoluble, water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 5 mg/ml, the liquid nicotine formulation having a water-insoluble, water-immiscible solvent content of greater than or equal to about 2 percent by weight. A cartridge containing the liquid nicotine formulation, and an aerosol-generating system, are also provided. 115.-. (canceled)16. A liquid nicotine formulation for an aerosol-generating system , the liquid nicotine formulation comprising:at least one of water and one or more water-miscible solvents;one or more partially water-soluble, water-immiscible solvents having a water solubility at 20° C. of between about 20 mg/ml and about 100 mg/ml; andone or more water insoluble, water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 5 mg/ml,wherein the liquid nicotine formulation has a water-insoluble, water-immiscible solvent content of greater than or equal to about 2 percent by weight.17. A liquid nicotine formulation for an aerosol-generating system , the liquid nicotine formulation comprising:at least one of water and one or more water-miscible solvents;one or more partially water-soluble, water-immiscible solvents having a partition coefficient (log P) at 20° C. of between about 0.05 and about 0.5; andone or more water insoluble, water-immiscible solvents a having a partition coefficient (log P) at 20° C. of greater than about 5,wherein the liquid nicotine formulation has a water-insoluble, water-immiscible solvent content of greater than or equal to about 2 percent by weight.18. The liquid nicotine formulation according to claim ...

DEVICES FOR EVAPORATION AND INHALATION OF ACTIVE AGENTS

There is provided an inhalation device for delivering a deliverable agent in the form of an aerosol or vapour to a user. The device comprises a solid, porous carrier material having a defined porosity, and a deliverable agent located within the pores of the carrier material. The device is operable to heat the carrier material and vaporise the deliverable agent. Deliverable agents that may be delivered to the user include active pharmaceutical ingredients. Suitable materials for the porous carrier material include chemically bonded ceramic materials and geopolymeric materials. 1. A device for delivering a deliverable agent in the form of an aerosol or vapour to a user , said device comprising a solid , porous carrier material having a porosity of at least 10% , and a deliverable agent located within the pores of the carrier material , wherein the device is operable to heat the carrier material and vaporise the deliverable agent.2. The device according to claim 1 , wherein the solid claim 1 , porous carrier material has a porosity of from about 20% to about 70%.3. The device according to or claim 1 , wherein the average pore size in the carrier material is from about 0.1 μm to about 500 μm claim 1 , preferably from about 0.2 μm to about 200 μm.4. The device according to any one of the preceding claims wherein the deliverable agent is located predominantly within the pores of the carrier material.5. The device according to any one of the preceding claims claim 1 , wherein the carrier material is based on one or more chemically bonded ceramic materials claim 1 , one or more geopolymeric materials or one or more metals.6. The device according to claim 5 , wherein the carrier material is selected from the list consisting of:a material obtainable by the process of reacting an aluminosilicate precursor material with an aqueous alkaline liquid; and(ii) a calcium phosphate, a calcium sulphate, a calcium carbonate, a calcium silicate, a calcium aluminate, a magnesium carbonate ...

SOLUTION COMPRISING NICOTINE IN UNPROTONATED FORM AND PROTONATED FORM

There is provided a nicotine solution comprising a carrier; nicotine in unprotonated form and in protonated form; and one or more acids, wherein at least benzoic acid, levulinic acid or a mixture thereof is present; and wherein the total content of acid present in the solution is no greater than 0.6 mole equivalents based on the nicotine. 124-. (canceled)25. A nicotine solution comprising:(i) a carrier;(ii) nicotine in unprotonated form and in protonated form; and(iii) one or more acids, wherein at least benzoic acid is present; andwherein the total content of acid present in the solution is no greater than 0.6 mole equivalents based on the nicotine.26. A nicotine solution according to further comprising water.27. A nicotine solution according to containing acid selected from the group consisting of benzoic acid.28. A nicotine solution according to wherein the total content of acid present in the solution is no greater than 0.5 mole equivalents based on the nicotine.29. A nicotine solution according to wherein the total content of acid present in the solution is no less than 0.2 mole equivalents based on the nicotine.30. A nicotine solution according to wherein the amount of benzoic acid present in the solution is no less than 0.2 mole equivalents based on the nicotine.31. A nicotine solution according to wherein the amount of benzoic acid present in the solution is from 0.2 to 0.4 mole equivalents based on the nicotine.32. A nicotine solution according to comprising nicotine in an amount of no greater than 2 wt % based on the total weight of the solution.33. A nicotine solution according to comprising nicotine in an amount of no greater than 1.8 wt % based on the total weight of the solution.34. A nicotine solution according to containing acid selected from the group consisting of levulinic acid and comprising nicotine in an amount of no greater than 1.8 wt % based on the total weight of the solution.35. A nicotine solution according to wherein the carrier is a ...

SUBSTANCES AND COMPOSITIONS FOR THE USE IN THE TREATMENT OF ENDOMETRIOSIS AND ENDOMETRIOSIS ASSOCIATED SYMPTOMS

The present invention relates to the use of Luteolin 2-(3,4-dihydroxyphenyl)-, 5,7dihydroxy-4-chromenone in a method for the treatment of endometriosis and symptoms thereof. The present invention further relates to compositions comprising Luteolin according to any administration route, alone or associated to other substances, such as for example antiandrogens, antiprogestins, progestins. 1. A method of treating endometriosis in a subject comprising administering a therapeutically effective amount of luteolin to a subject in need thereof.2. A method of treating endometriosis in a subject comprising administering a therapeutically effective amount of a composition comprising luteolin and optionally one or more excipients and/or diluents and/or carriers.3. The method of claim 2 , wherein the composition further comprises one or more antiandrogens claim 2 , antiprogestins claim 2 , progestins claim 2 , other flavonoids.4. The method of claim 2 , wherein said luteolin per dosage unit is between 0.01 mg and 100 grams.5. The method of claim 2 , wherein one or more symptoms associated with endometriosis is selected among acute and chronic pelvic pain claim 2 , dyspareunia claim 2 , dysmenorrhea claim 2 , pain related to ovulation claim 2 , pain due to urination claim 2 , pain in the intestinal functions claim 2 , chronic physical fatigue claim 2 , headache claim 2 , female infertility and decrease in endometriosis outbreaks.6. The method of claim 2 , wherein said luteolin is comprised in a plant extract.7Tomato salvia,Aiphanes aculeata. The method of claim 2 , wherein said plant extract is an extract of Clover claim 2 , Ambrosia pollen claim 2 , mint claim 2 , celery claim 2 , broccoli claim 2 , peppers claim 2 , parsley claim 2 , thyme claim 2 , dandelion claim 2 , perilla claim 2 , camomile tea claim 2 , carrots claim 2 , olive oil claim 2 , peppermint claim 2 , rosemary claim 2 , palm seeds claim 2 , or the shells of peanuts.8Tanacetum parthenium. The method of claim 2 , ...

NICOTINE SALT FORMULATIONS FOR AEROSOL DEVICES AND METHODS THEREOF

A nicotine salt liquid formulation for generating an inhalable aerosol in an electronic cigarette comprising nicotine salt that forms about 0.5% to about 20% nicotine is provide. 1. A method of delivering nicotine from an inhalable aerosol so that the inhaled aerosol causes a physiological response similar to smoking a tobacco cigarette , the method comprising:deploying an electronic cigarette comprising a nicotine salt formulation that includes nicotine, a carboxylic acid, and a biologically acceptable liquid carrier, wherein:a. the nicotine concentration is from about 0.5% (w/w) to about 20% (w/w);b. the nicotine is protonated;c. the biologically acceptable liquid carrier comprises propylene glycol and glycerol; andresistively heating at least a portion of the nicotine salt formulation to generate an inhalable aerosol comprising protonated nicotine.2. The method of claim 1 , wherein the nicotine salt formulation comprises nicotine lactate.3. The method of claim 1 , wherein the carboxylic acid comprises one or more of: pyruvic acid claim 1 , salicylic acid claim 1 , sorbic acid claim 1 , lauric acid or benzoic acid.4. The method of claim 1 , wherein deploying results in an increase in heart rate comparable to an increase in heart rate resulting from inhalation of traditional burned tobacco.5. The method of claim 1 , wherein a molar ratio of nicotine to carboxylic acid is between 1:1 and 1:3.6. The method of claim 1 , wherein the nicotine salt formulation further comprises at least one flavorant.7. The method of claim 1 , wherein the nicotine concentration is about 4.5%.8. The method of claim 1 , wherein inhalation of the aerosol into the user's lungs over a period of about 5 minutes at a rate of about one inhalation per 30 seconds results in a nicotine plasma Tmax from about 3 min to about 8 min.9. The method of claim 1 , wherein the inhalable aerosol has a particle size from about 0.1 microns to about 5 microns.10. A method of delivering nicotine from an inhalable ...

NICOTINE SALT FORMULATIONS FOR AEROSOL DEVICES AND METHODS THEREOF

A nicotine salt liquid formulation for generating an inhalable aerosol in an electronic cigarette comprising nicotine salt that forms about 0.5% to about 20% nicotine is provided. 1. A method of delivering nicotine to a user comprising: a. the nicotine concentration is from about 0.5% (w/w) to about 20% (w/w);', 'b. the nicotine formulation comprises nicotine lactate;', 'c. the biologically acceptable liquid carrier comprises propylene glycol and glycerol; and', 'd. operation of the electronic cigarette comprises heating at least a portion of the nicotine formulation to generate an inhalable aerosol., 'deploying an electronic cigarette comprising a nicotine formulation that comprises nicotine, an organic acid, and a biologically acceptable liquid carrier, wherein2. The method of claim 1 , wherein a molar ratio of nicotine to organic acid is between about 1:1 and 1:3.3. The method of claim 1 , wherein the nicotine formulation further comprises at least one flavorant.4. The method of claim 1 , wherein the nicotine concentration is about 4.5%.5. The method of claim 1 , wherein inhalation of the aerosol into the user's lungs over a period of about 5 minutes at a rate of about one inhalation per 30 seconds results in a nicotine plasma Tmax from about 3 min to about 8 min.6. The method of claim 1 , wherein the inhalable aerosol has a particle size from about 0.1 microns to about 5 microns.7. A method of delivering nicotine to a user comprising: a. the nicotine concentration is from about 0.5% (w/w) to about 20% (w/w);', 'b. the nicotine formulation comprises protonated nicotine;', 'c. the biologically acceptable liquid carrier comprises propylene glycol and glycerol;', 'd. the acid does not decompose at room temperature and does not decompose at the operating temperature of the electronic cigarette; and', 'e. operation of the electronic cigarette comprises heating at least a portion of the nicotine formulation to generate an inhalable aerosol., 'deploying an electronic ...

TRANSDERMAL DEVICE INCLUDING POROUS MICROPARTICLES

The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle. 1. A self-adhesive transdermal device , including the association of a support layer and a self-adhesive matrix layer and a detachable protective film , said self-adhesive matrix layer including , in relation to the total weight of the self-adhesive matrix layer:a. 65 to 93% by weight of at least one self-adhesive polymer selected from the group comprising polymers of the acrylic or acrylate type, polymers of the silicone type, polymers of the vinyl acetate type, natural or synthetic gums, copolymers thereof and mixtures thereof;b. 2 to 15% by weight of at least one microporous solid polymer capable of containing an active principle, said polymer being comprised of monomer units selected from the group of monomers comprising styrene, divinylbenzene, methyl methacrylate, ethylene glycol dimethacrylate, 4-vinylpyridine, lauryl methacrylate, allyl methacrylate, glycol dimethacrylate, and mixtures thereof; andc. 5 to 20% by weight of active principle.2. The device according to claim 1 , wherein the active principle is nicotine.3. The device according to claim 1 , wherein the self-adhesive polymer is of the acrylic or acrylate type and is comprised of monomers selected from the group comprising vinyl acetate claim 1 , 2-ethylhexyl acrylate claim 1 , butyl acrylate claim 1 , acrylic acid claim 1 , methyl methacrylate claim 1 , methyl acrylate claim 1 , tert-octyl acrylamide claim 1 , 2-hydroxy ethyl acrylate claim 1 , glycidyl methacrylate claim 1 , or mixtures thereof.4. The device according to claim 3 , wherein the monomers are selected from the group comprising acrylic acid claim 3 , butyl acrylate ...

TABLETTABLE CHEWING GUMS

The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking. 1. A chewing gum for use in nicotine replacement therapy , which provides rapid nicotine release in the oral cavity and fast—but non-toxic , pharmaceutically acceptable—buccal absorption of nicotine , and which is characterized by comprising a compressible chewing gum base that allows the chewing gum to be manufactured by tabletting , at least one nicotine active selected from the group consisting of pharmaceutically acceptable salts of nicotine and pharmaceutically acceptable nicotine complexes and resins , and at least one buffering agent.2. A chewing gum according to claim 1 , wherein the at least one nicotine active and the at least one buffering agent are present in homogeneous mixture.3. A chewing gum according to or claim 1 , wherein the at least one nicotine active is selected from the group consisting of pharmaceutically acceptable salts of nicotine.4. A chewing gum according to any one of - claim 1 , which is characterized by comprising the at least one nicotine active in an amount corresponding to from 0.2 to 8 mg of nicotine free base.5. A chewing gum according to any one of - claim 1 , wherein the at least one buffering agent is selected from the group consisting of alkali metal carbonates and alkali metal bicarbonates claim 1 , alkaline earth metal carbonates claim 1 , alkali metal citrates and alkali metal phosphates.6. A chewing gum according to any one of - claim 1 , which comprises two different buffering agents claim 1 , the first one thereof being an alkali metal carbonate and the second one thereof being an alkali metal bicarbonate.7. A chewing gum according to or claim 1 , which comprises claim 1 , as buffering agents claim 1 , sodium carbonate and sodium bicarbonate in the form of coated particles claim 1 , ...

Methods of Treating Cancers, Autoimmune Disorders, and Other Conditions Associated with Chronic Inflammation

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).

Medical product and method for eliminating symptoms of nicotine withdrawal

In essence, the present invention relates to a medical product including between about 94% and about 98% of a saline solution, preferably a normal saline solution containing about 0.9% sodium chloride dissolved in water, about ⅛ th of 1 milligram of relatively pure nicotine and about 3 milligrams of relatively pure nicotine. The medical product also includes about 1% and 3% of one or more flavors selected from the group consisting of citrus, tobacco, apple, cherry, maple, menthol, hazelnut, peach, lemon, vanilla and chocolate and 1% citric acid for taste. In addition, the medical product includes about 1% to 2% of ethyl alcohol for cleaning a micron mesh grid that generates particles of pure nicotine of from 2 to 5 microns that are drawn through an entrainment port, through a capsule containing the medical product through the micron mesh grid and into the individual's lungs and into their bloodstream.

Methods of Regulating Oxidoreductase Activity for Treatment of Inflammation and Age-Related Disorders

In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder involves administering to an individual isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, a method of treating oxidative stress associated with an inflammation or age-related disorder involves administering to an individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of infectious or parasitic diseases or various other disorders. 1. A method of regulating oxidoreductase activity for treating an inflammation or age-related disorder comprising administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof , and a pharmaceutically acceptable vehicle therefor.2. The method of claim 1 , wherein the therapeutically effective amount is from about 0. 001 to about 75 mg/kg/day.3. The method of claim 1 , wherein the therapeutically effective amount is from about 0.01 to about 50 mg/kg/day.4. The method of claim 1 , wherein the therapeutically effective amount is from about 0.1 to about 40 mg/kg/day.5. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 30 mg/kg/day.6. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 20 mg/kg/day.7. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 10 mg/kg/day.8. A method of treating oxidative stress associated with an inflammation or age-related disorder comprising administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable vehicle therefor.9. The method of claim 8 , wherein the ...

GUM RESIN AS A CARRIER FOR TOPICAL APPLICATION OF PHARMACOLOGICALLY ACTIVE AGENTS

Described are pharmacological compositions comprising a gum resin; a pharmacologically active agent and a topically acceptable volatile solvent for the gum resin and active agent. Also described are methods for the transdermal or transmucosal delivery of a pharmacologically active agent using such compositions. 132-. (canceled)33. A liquid pharmacological composition comprising:(a) a gum resin;(b) an active agent selected from the group consisting of nicotine, nitroglycerin and scopolamine; and(c) a topically acceptable volatile solvent for said gum resin and said active agent.34. The composition according to claim 33 , wherein said gum resin is selected from the group consisting of benzoin gum and mastic gum.35. The composition according to claim 33 , wherein said topically acceptable volatile solvent comprises about 40% to 90% of said composition.36. The composition according to claim 33 , wherein said topically acceptable volatile solvent comprises ethanol.37. The composition according to claim 36 , wherein said topically acceptable volatile solvent comprises about 60% to 90% of said composition.38. The composition according to claim 33 , further comprising a penetration enhancer.39. The composition according to claim 33 , wherein the composition is formulated for transmucosal administration.40. The composition according to claim 33 , wherein the active agent is nicotine.41. The composition according to claim 33 , wherein the active agent is nitroglycerin claim 33 ,42. The composition according to claim 33 , wherein the active agent is scopolamine. This application is a continuation in part of U.S. Ser. No. 10/053,313 filed Jan. 18, 2002 which claims benefit of priority to provisional application U.S. Ser. No. 60/299,377 filed Jun. 18, 2001, which disclosures are hereby incorporated by reference.1. Technical FieldThe invention relates to gum resin or other film forming agent based biological dressings that adhere to the skin and contain one or more ...

NICOTINE FORMULATION AND AEROSOLS

The present disclosure generally relates to nicotine formulations, nebulizer systems comprising same and uses thereof via inhalation. 135.-. (canceled)36. An aqueous nicotine formulation comprising nicotine and a buffer , the formulation is having a pH within the range of 3.5 to 4.5 , wherein the nicotine is having a purity of at least 95% and wherein the percentage of nicotine based on the total mass of the formulation is within the range of 0.5 to 8%.37. The aqueous nicotine formulation of claim 36 , wherein the buffer is a citrate buffer.38. The aqueous nicotine formulation of claim 36 , wherein said formulation is an aerosol having a pH of about 4.39. The aqueous nicotine formulation of claim 36 , wherein said formulation is an aerosol devoid of propellants.40. The aqueous nicotine formulation of claim 36 , wherein the concentration of nicotine in the formulation is within the range of 10 to 40 mg/ml.41. The aqueous nicotine formulation of claim 36 , having a pH of about 4.42. The aqueous nicotine formulation of claim 36 , further comprising a sweetener selected from the group consisting of saccharine claim 36 , aspartame claim 36 , dextrose and fructose.43. The aqueous nicotine formulation of claim 36 , further comprising at least one anti-coughing agent selected from expectorants claim 36 , antitussives or both.44. An aerosol comprising an aqueous nicotine formulation claim 36 , said aerosol comprising droplets having an MMAD of at most 10 microns claim 36 , wherein the aqueous nicotine formulation comprises nicotine and a buffer claim 36 , having a pH within the range of 3.5 to 4.5 claim 36 , and wherein the nicotine is having a purity of at least 95%.45. The aerosol of claim 44 , comprising droplets having an MMAD within the range of 0.3 to 7 microns.46. The aerosol of claim 44 , comprising droplets having an MMAD is less than 5 microns.47. The aerosol of claim 44 , comprising droplets having droplets having a GSD within the range of 2-5 μm.48. The aerosol ...

TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING NICOTINE AND SILICONE ACRYLIC HYBRID POLYMER

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of nicotine comprising a nicotine-containing layer structure, said nicotine-containing layer structure comprising A) a backing layer and B) a nicotine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer. 2. Transdermal therapeutic system according to claim 1 ,wherein the silicone acrylic hybrid polymer is a silicone acrylic hybrid pressure-sensitive adhesive.3. Transdermal therapeutic system according to or claim 1 ,wherein the nicotine-containing layer is a matrix layer, and preferably is a nicotine-containing pressure-sensitive adhesive layer.4. Transdermal therapeutic system according to any one of to claim 1 , 1. nicotine; and', '2. the silicone acrylic hybrid polymer., 'wherein the nicotine-containing layer comprises5. Transdermal therapeutic system according to any one of to claim 1 ,{'sup': 2', '2', '2, 'wherein the nicotine-containing layer comprises at least 0.90 mg/cm, preferably at least 0.95 mg/cm, more preferably at least 1.15 mg/cmnicotine, and/or'}{'sup': 2', '2', '2', '2', '2, 'wherein the nicotine-containing layer comprises less than 5.0 mg/cm, less than 4.0 mg/cm, less than 3.0 mg/cm, less than 2.0 mg/cmor less than 1.7 mg/cmnicotine.'}6. Transdermal therapeutic system according to any one of to claim 1 ,{'sup': 2', '2', '2', '2', '2, 'wherein the area weight of the nicotine-containing layer is at least 80 g/mor is at least 90 g/mor ranges from 80 to 300 g/m, preferably from 90 to 270 g/m, and more preferably from 100 to 230 g/m.'}7. Transdermal therapeutic system according to any one of to claim 1 ,wherein the amount of nicotine in the nicotine-containing layer ranges from 2 to 15%, preferably from 3 to 12% and more preferably from 4 to 10% of the nicotine-containing layer, and/orwherein the amount of nicotine contained in the transdermal therapeutic system ranges from 5 to 90 mg, preferably ...

Terpene Carrier

Delivery of active ingredients by administration to an individual a vapor, aerosol, or liposomal suspension. Certain terpene solutions are employed for delivery. 1. A terpene carrier composition comprising a mixture of terpenes as a carrier for the one or more active ingredient for vaporizers or liposomal transport wherein the mixture of terpenes comprises a first terpene selected from myrcene , nerolidol , beta caryophyllene or a mixture thereof and one or more second terpenes selected from the group consisting of limonene , pinene , linalool , terpineol , terpinolene , terpineol , menthol and a mixture thereof.2. The composition of comprising a mixture of two or more terpenes selected from the group consisting of myrcene claim 1 , beta-caryophyllene claim 1 , linalool claim 1 , or limonene.3. The composition of comprising a mixture of myrcene and beta-caryophyllene and one of linalool or limonene.4. The composition of comprising a mixture of beta-caryophyllene claim 1 , one of linalool or limonene and a combination of myrcene and neurolidol.5. The composition of claim 1 , wherein the amount of first terpene present ranges from 50% to 100% by weight.6. The composition of claim 1 , wherein the amount of second terpene present ranges from 1% to 25% by weight.7. The composition of claim 1 , wherein the first terpene is a mixture of myrcene and beta-caryophyllene claim 1 , where the weight ratio of myrcene to beta-caryophyllene ranges from 4:1 to 1:4.8. The composition of claim 7 , wherein the weight ratio of myrcene to beta-caryophyllene is 1:1.9. A composition of further comprising one or more isolated cannabinoid receptor modulator or nicotine.10. The composition of claim 9 , wherein the composition comprises 10% by weight or more of the one or more isolated cannabinoid receptor modulators.11. The composition of claim 10 , wherein the one or more isolated cannabinoid receptor modulator is selected from THC claim 10 , CBD claim 10 , CBC claim 10 , CBG or a mixture ...

FILMS AND LAMINATES FOR USE IN PACKAGING REACTIVE COMPOUNDS

The present present disclosure relates to a laminate film including a water resistant or oxygen resistant base layer, and co-extrusion layer. The coextrusion layer may include a tie layer and a contact layer, and the contact layer may include a polymer such as cyclic olefin copolymer, a polyamide, or an ethylene vinyl alcohol. A total loading of the tie layer may be in the range of 3-9 g/mand wherein a loading of the contact layer is: loading=x*loading, wherein loadingis the loading of the contact layer, loadingis the total loading of the tie layer, and x is in the range of 0.8 to 3. 1. A laminate film comprising:a base layer, wherein the base layer is one or more of water or oxygen resistant; anda co-extrusion layer, the co-extrusion layer comprising a tie layer and a contact layer, wherein the contact layer comprises a polymer selected from the group consisting of a cyclic olefin copolymer, a polyamide, an ethylene vinyl alcohol, or a combination thereof;{'sup': '2', 'wherein a total loading of the tie layer is in the range of 3-9 g/mand wherein a loading of the contact layer is{'sub': contact', 'tie', 'contact', 'tie, 'loading=x*loading, wherein loadingis the loading of the contact layer, loadingis the total loading of the tie layer, and x is in the range of 0.8 to 3.'}2. The laminate film according to claim 1 , wherein x is in the range of 1 to 3.3. The laminate film according to claim 1 , wherein x is in the range of 1.33 to 2.75.4. The laminate film according to claim 1 , wherein the tie layer is a multilayered tie layer comprising at least two layers.5. The laminate film according to claim 1 , wherein at least one layer of the multilayered tie layer is made from a material selected from the group consisting of: ethylene methacrylic acid claim 1 , ethylene acrylic acid claim 1 , terpolymer of ethylene claim 1 , acrylic ester claim 1 , and maleic anhydride claim 1 , preferably ethylene claim 1 , butyl acrylate claim 1 , maleic anhydride claim 1 , or a ...

TOPICAL FILM DELIVERY SYSTEM

The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release. The formed film is characterized by: locally sustained levels of a minimum effective concentration (MEC) of the active agent between applications; its adherence and conformance to a surface of the skin; its pliability, its resistance to breaking under tension (tensile strength); maintained potency of the active agent; and removability of the film from the skin without a residue. 1. A topical bioadhesive film-forming pharmaceutical composition for application directly to skin or to a substrate comprising:(a) a therapeutic amount of an active agent;(b) a non-cellulosic polymer or copolymer;(c) a film forming agent;(d) a plasticizer;(e) a permeation enhancer; and(f) an antioxidant,the film-forming composition being characterized byA. controlled release of locally sustained levels of a minimum effective concentration (MEC) of the active agent;B. it is effective to conform to a surface of the skin during movement without breaking,C. it is of a quality or tendency to bend that does not require force or pressure from the outside; andD. it can be ...

TOPICAL FILM DELIVERY SYSTEM

The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release. The formed film is characterized by: locally sustained levels of a minimum effective concentration (MEC) of the active agent between applications; its adherence and conformance to a surface of the skin; its pliability, its resistance to breaking under tension (tensile strength); maintained potency of the active agent; and removability of the film from the skin without a residue. 1. A topical bioadhesive film-forming pharmaceutical composition for application directly to skin or to a substrate comprising:(a) a therapeutic amount of an active agent; and(b) one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance A. Its maintenance of sustained levels of the active agent locally or systemically;', 'B. its conformance to a surface of the skin without breaking,', 'C. its pliability; ...

Liquid nicotine formulation

A liquid nicotine formulation for an aerosol-generating system is provided, the liquid nicotine formulation including: water and one or more water-miscible solvents, the liquid nicotine formulation having a water content of greater than or equal to about 30 percent by weight and a water-miscible solvent content of greater than or equal to about 10 percent by weight, a ratio of the weight percent water content to a weight percent water-miscible solvent content of the liquid nicotine formulation being greater than or equal to about 1, the liquid nicotine formulation having a glycerine content of greater than or equal to about 6 percent by weight, and the liquid nicotine formulation having at least one of: a water content of greater than or equal to about 45 percent by weight, and a combined water and water-miscible solvent content of greater than or equal to about 70 percent by weight.

ORAL PRODUCT WITH NICOTINE AND ION PAIRING AGENT

The disclosure provides compositions configured for oral use, the compositions including at least one filler, water, a basic amine, and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a log P value of from about 1.4 to about 8.0. At least a portion of the basic amine is associated with at least a portion of the organic acid or the alkali metal salt thereof. The association is in the form of a basic amine-organic acid salt, an ion pair between the basic amine and a conjugate base of the organic acid, or a combination of both. Further provided are methods for stabilizing a composition configured for oral use and for enhancing a predicted buccal absorption of a composition configured for oral use. 1. A composition configured for oral use , the composition comprising:at least one filler;a basic amine;water; andan organic acid, an alkali metal salt of an organic acid, or a combination thereof;wherein the organic acid has a log P value of from about 1.4 to about 8.0, andat least a portion of the basic amine is associated with at least a portion of the organic acid or the alkali metal salt thereof, the association in the form of a basic amine-organic acid salt, an ion pair between the basic amine and a conjugate base of the organic acid, or both.2. The composition of claim 1 , wherein the organic acid has a log P value of from about 1.4 to about 4.5.3. The composition of claim 1 , wherein the organic acid has a log P value of from about 2.5 to about 3.5.4. The composition of claim 1 , wherein the organic acid has a log P value of from about 4.5 to about 8.0 claim 1 , and wherein the composition further comprises a solubility enhancer.5. The composition of claim 4 , wherein the solubility enhancer is glycerol or propylene glycol.6. The composition of claim 1 , comprising from about 0.05 claim 1 , about 0.1 claim 1 , about 1 claim 1 , about 1.5 claim 1 , about 2 claim 1 , or about 5 claim 1 , to about 10 claim ...

TRANSPARENT TRANSDERMAL NICOTINE DELIVERY DEVICES

A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%. 19-. (canceled)10. A method for transdermal administration of nicotine , the method comprising: a backing layer comprising a material selected from the group consisting of PET/EVA laminates, HDPE/EAA/nylon/EAA multilaminate, and a film comprising a graft copolymer formed from about 73-77% acrylonitrile and from about 23-27% methyl acrylate copolymerized in the presence of about 8-10 parts by weight of butadiene/acrylonitrile copolymers; and', 'a drug reservoir layer comprising nicotine,', 'wherein the device is sufficiently transparent to permit the skin surface to be visible through the device., 'applying a transdermal nicotine delivery device to a skin surface, the device comprising11. The method of claim 10 , wherein the drug reservoir layer further comprises a self-adhesive drug reservoir.12. The method of claim 10 , wherein the drug reservoir layer further comprises one or more adhesives.13. The method of claim 12 , wherein the one or more adhesives comprises one or more pressure sensitive adhesives selected from the group consisting of polysiloxanes claim 12 , polyacrylates claim 12 , polyurethanes claim 12 , acrylic adhesives claim 12 , vinyl acetate adhesives claim 12 , ethylene vinyl acetate copolymers claim 12 , natural or synthetic rubbers claim 12 , and mixtures and graft copolymers thereof.14. The method of claim 10 , wherein the device is provided with one or more hydrophilic water absorbing polymers.15. The method of claim 10 , wherein the backing layer has a nicotine permeability of less than 1.0 μg/cm/hr.16. The method of claim 10 , wherein the backing layer has a nicotine permeability of less than 0.5 μg/cm/hr.17. The method of claim 10 , wherein the backing layer has a solubility for nicotine of less than 1 wt %.18. The method of claim 10 , wherein the backing layer has a solubility for nicotine of less than 0.1 wt %.19. The method of ...

COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS

The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease. 1. A pulsatile release dosage form for twice-daily administration , said form comprising a capsule or tablet comprising an effective amount of nicotine for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease , wherein said capsule or tablet exhibits pulsatile release of said nicotine.2. The dosage form according to claim 1 , wherein said pulsatile release comprises a first and second release peak claim 1 , wherein said first release peak occurs within about two hours of administration to a patient claim 1 , and said second release peak occurs between about two and about twelve hours of administration to a patient.3. The dosage form according to claim 2 , wherein said dosage form is a capsule.4. The dosage form according to claim 3 , wherein said capsule comprises a powder comprising nicotine for providing said first release peak upon administration to a patient claim 3 , and said capsule further comprises beads comprising nicotine for providing said second release peak upon administration to a patient.5. The dosage form according to claim 4 , wherein said beads are selected from the group consisting of enteric-coated beads claim 4 , erodible-matrix beads claim 4 , wax-coated beads claim 4 , ethylcellulose-coated beads claim 4 , silicone elastomer coated beads claim 4 , and combinations thereof.6. The dosage form according to claim 3 , wherein said capsule comprises a water-swellable polymeric membrane.7. The dosage form according to claim 6 , wherein said water-swellable polymeric membrane ruptures following administration to a patient.8. The dosage form according to claim 2 , wherein said dosage form is a tablet.9. The dosage form according to claim 8 , ...

Low viscosity liquid nicotine formulation

A liquid nicotine formulation for an aerosol-generating system is provided, the liquid nicotine formulation including: glycerine and having a viscosity at 20° C. of less than or equal to about 20 mPa·s, wherein the liquid nicotine formulation being a substantially uncaffeinated liquid nicotine formulation, and the liquid nicotine formulation having a glycerine content of greater than or equal to about 6 percent by weight. A cartridge for an aerosol-generating system, and an aerosol-generating system, are also provided.

LIQUID NICOTINE FORMULATION

A liquid nicotine formulation for an aerosol-generating system is provided, the liquid nicotine formulation including: one or more water-miscible solvents; one or more water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 100 mg/ml; and one or more water-soluble organic acids, the liquid nicotine formulation having a water-immiscible solvent content of greater than or equal to about 2 percent by weight. A cartridge for an aerosol-generating system, and an aerosol-generating system, are also provided. 115.-. (canceled)16. A liquid nicotine formulation for an aerosol-generating system , the liquid nicotine formulation comprising:one or more water-miscible solvents;one or more water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 100 mg/ml; andone or more water-soluble organic acids,wherein the liquid nicotine formulation has a water-immiscible solvent content of greater than or equal to about 2 percent by weight.17. A liquid nicotine formulation according to claim 16 , wherein the one or more water-immiscible solvents comprise one or more partially water-soluble solvents having a water solubility at 20° C. of between about 20 mg/ml and about 100 mg/ml.18. A liquid nicotine formulation according to claim 16 , wherein the one or more water-immiscible solvents comprise one or more water-insoluble solvents having a water solubility at 20° C. of less than or equal to about 5 mg/ml19. A liquid nicotine formulation for an aerosol-generating system claim 16 , the liquid nicotine formulation comprising:one or more water-miscible solvents;one or more water-immiscible solvents having a partition coefficient (log P) at 20° C. of greater than or equal to about 0.05; andone or more water-soluble organic acids,wherein the liquid nicotine formulation has a water-immiscible solvent content of greater than or equal to about 2 percent by weight.20. The liquid nicotine formulation according to claim 19 , ...

SOLID MICELLAR COMPOSITIONS OF CANNABINOID ACIDS

Solid, micellar compositions, comprising micelles of one or more cannabinoid acids and a metal, wherein the cannabinoid acids are in a salt form, the salt form has a monovalent counter ion, and the micelles are free of added surfactants, are disclosed. Additionally, processes for preparing solid, micellar compositions, comprising micelles of one or more cannabinoid acids and a metal, wherein the cannabinoid acids are in a salt form, the salt form has monovalent counter ion, and the micelles are free of added surfactants, are disclosed. Finally, methods of treating a number of disorders comprising the step of administering to a patient in need thereof a therapeutically effective amount of a solid, micellar composition comprising micelles of one or more cannabinoid acids and a metal, wherein the cannabinoid acids are in a salt form, the salt form has monovalent counter ion, and the micelles are free of added surfactants, are disclosed. 1. A solid , micellar composition , comprising micelles of one or more cannabinoid acids and a metal , wherein:the one or more cannabinoid acids are in a salt form, the salt form having a monovalent counter ion;the micelles are free of added surfactants; andthe micelles comprise an outer hydrophilic portion and an inner hydrophobic portion.2. The composition of claim 1 , wherein the one or more cannabinoid acids are selected from the group consisting of: CBDa claim 1 , THCa claim 1 , and CBGa.3. The composition of claim 1 , wherein the monovalent cation is selected from the group consisting of: lithium claim 1 , sodium claim 1 , potassium claim 1 , rubidium claim 1 , cesium claim 1 , and ammonium.4. The composition of claim 1 , wherein the metal is selected from the group consisting of: an s-block metal claim 1 , a d-block metal claim 1 , and a p-block metal.5. The composition of claim 4 , wherein the metal is selected from the group consisting of: magnesium claim 4 , calcium claim 4 , and strontium.6. The composition of claim 1 , ...

METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTION

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit. 1. A method of treating wounds comprising administering to a patient in need thereof a composition comprising substances dissolved in water , the substances comprising ascorbic acid , thiamine HCl , magnesium sulfate , cyanobalamin , a B-vitamin , pyridoxine HCl , riboflavin 5′-phosphate , calcium D-pantothenate , sodium bicarbonate , and sodium chloride.2. The method of claim 1 , wherein the ascorbic acid is at a concentration from about 100 mg to about 500 mg claim 1 , the thiamine is at a concentration from about 1 mg to about 100 mg claim 1 , the magnesium sulfate is at a concentration from about 100 mg to about 500 mg claim 1 , the cyanobalamin is at a concentration from about 100 .mu.g to about 500 .mu.g claim 1 , the B-vitamin is at a concentration from about 1 mg to about 300 mg claim 1 , the pyridoxine HCl is at a concentration from about 1 mg to about 100 mg claim 1 , the riboflavin 5′-phosphate is at a concentration from about 1 mg to about 100 mg claim 1 , and the calcium D-pantothenate is at a concentration from about 1 mg to about 100 mg.3. The method of claim 1 , wherein the composition further comprises at least one of trace metals claim 1 , 2 di-methyl amino ethanol HCl claim 1 , lipoic acid claim 1 , folic acid claim 1 , an antibiotic claim 1 , vitamins claim 1 , vitamers claim 1 , salts claim 1 , acids claim 1 , amino acids claim 1 , an anesthetic claim 1 , trace metals claim 1 , and heparin.4. The method of claim 3 , wherein the composition comprises the antibiotic.5. The method of claim 4 , wherein the antibiotic ...

Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.

METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS

Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents using tapioca starch or related compounds. Lipophilic active agents include cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins. 121-. (canceled)22. A lipophilic active agent infused food product comprising:(a) a therapeutically effective amount of a lipophilic active agent, wherein the lipophilic active agent is selected from the group consisting of a cannabinoid, nicotine, a non-steroidal anti-inflammatory drug (NSAID), and a vitamin;(b) an edible oil or fat;(c) a starch, wherein the starch is selected from the group consisting of tapioca starch, corn starch, potato starch, oxidized starch, starch ester, starch ether, crosslinked starch, alpha starch, octenylsuccinate ester, and processed starch obtained by treating a starch by an acid, heat, or enzyme; and(d) a food product, wherein the food product is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.242. The lipophilic active agent infused food product of claim , wherein step (i) comprises saturating the food product in the edible oil comprising the lipophilic active agent.253. The lipophilic active agent infused food product of claim , further comprising a bioavailability enhancing agent , wherein the bioavailability enhancing agent enhances the bioavailability of the lipophilic active agent.264. The lipophilic active agent infused food product of claim , wherein step (i) comprises saturating the food product in an edible oil comprising the lipophilic active agent and the bioavailability enhancing agent.271. The lipophilic active agent infused food product of claim , wherein ...

NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION

A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy. 127-. (canceled)28. A method of preparing a nicotine-containing pharmaceutical composition , comprising:(i) mixing a non-hygroscopic sugar substitute capable of forming a glassy matrix in an amount of at least about 80% by weight and a sugar alcohol syrup in a melted state to form a mixture;(ii) cooling the mixture and incorporating a nicotinic compound into the cooled mixture; and(iii) further cooling the mixture to room temperature to form a solid nicotine-containing pharmaceutical composition.29. The method of claim 28 , wherein at least a portion of the nicotinic compound is in the form of a free base claim 28 , a salt claim 28 , a complex claim 28 , or a solvate.30. The method of claim 28 , wherein the nicotinic compound is nicotine polacrilex.31. The method of claim 28 , wherein the nicotinic compound is sorbed onto a porous particulate carrier.32. The method of claim 31 , wherein the porous particulate carrier comprises microcrystalline cellulose.33. The method of claim 28 , wherein the sugar substitute is isomalt.34. The method of claim 28 , wherein the sugar alcohol syrup is in an amount sufficient to slow recrystallization of the sugar substitute in melted form.35. The method of claim 28 , wherein the sugar alcohol syrup is maltitol syrup or xylitol syrup.36. The method of claim 28 , wherein the pharmaceutical composition comprises at least about 85% by weight of the sugar substitute.37. The method of claim 28 , wherein the pharmaceutical composition comprises at least about 4.0% by weight ...